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„Remember, all we are trying to do is kill the cancer faster than we kill the patient! “ 
James F. Leary, Ph.D. 
Endowed Professor of Nanomedicine 
Full Professor of Basic Medical Sciences, School of Veterinary Medicine 
Purdue University 
  
Although medicine has made great progress in the last centuries and decades, 
it is still facing basic challenges that make doctors fail to efficiently and successfully 
treat the continuously emerging diseases and ailments due to ageing, 
industrialization, pollution and resulting biological mutations. In this context, the 
systemic chemotherapeutic treatment of cancer seems to be one of the most fitting 
examples for the wide gap between the usually followed medical approach and the 
theoretically optimal solution. 
Extrapolating from in vitro experiments and mouse models to humans, treating 
children as “miniaturized” adults when analyzing therapeutic effects, estimating drug 
doses based on relatively coarse processes like up scaling on weight, volume or area, 
and flooding the human body with drugs to solely achieve a minimal effect at the 
ailment site are just few examples for improvement needs in medical methods. 
One of the most promising approaches intended to bring more specificity and 
precision into the therapeutic toolbox is the directed delivery of drugs, already 
prophesized and described one hundred years ago by the German immunologist and 
Nobel Laureate in Medicine (1908) Paul Ehrlich (1854-1915) as the “magic bullet” 
principle.  It  is  a  visionary medical  method in which active agents -such as drugs or  
antibodies- are guided within the human body and brought to bind directly and 
exclusively to their biological target. This approach was triggered and has been 
remarkably promoted by the introduction and continuous development of nano-
sized medical systems since the 1950s, and is expected to experience a real 
breakthrough by the clinical validation of the so called “Magnetic Drug Targeting”. 
According to this technique, magnetically active nanoparticles are coated with 
a therapeutically active biomaterial and guided through external magnetic fields in 
the natural transport pathways of the body, then retained and concentrated at 
target sites where the biologically active load is set free. The delivered dose is 
augmented, side effects are lowered and the overall therapeutic efficiency is 
enhanced. 
Especially for cancer treatment, the magnetically guided drug delivery 





systemically and succeed in best cases in delivering only a fractional amount of the 
drug to the target sites, while the rest is absorbed by the healthy tissue of the 
treated body. This is so inefficient that dose levels of about 50 to 100-fold those of 
conventional doses need to be administered to achieve cures of cancer cells (T. A. 
Connors 1995). As a result, blood filtering and trafficking organs, such as the liver, the 
kidneys, the spleen and most importantly the heart, are the direct victims of the 
highly toxic substances used in chemotherapy. Even the apparently more gentle 
approach of applying the maximum tolerated dose at defined intervals -in order to 
avoid toxicity- can unintentionally lead to a chemoresistance of the tumor (C. 
Damyanov 2009). These shortcomings of the chemical therapy further aggravate the 
fact that cancer is still the worldwide deadliest disease, with an upward trend. For 
instance, around 25 % of all registered death cases in the European Union are 
reported by the World Health Organization to be caused by tumors. Despite the 
development of advanced anti-cancer medicine, it still remains a difficult challenge 
to keep costs at an affordable level. For that reason, new and more efficient cancer 
treatment  methods  with  higher  success  rates  and  lower  side  effects  and  costs  are  
urgently needed and would help physicians cope with an ever ageing world 
population. 
 
In this work, we report improvements achieved in the understanding and 
control of the magnetically targeted drug delivery, mainly realized by the 
consideration of time issues and the investigation of dynamic magnetic fields. New 
approaches to assess the magnetic behavior of nanoparticles in suspensions as well 
as an advanced examination of the lung drug targeting and the mechanisms of 
cellular drug uptake after successful localized delivery represent the major 
achievements compiled in this manuscript. 
The registered improvements are an important contribution to the further 
development of the idea of directed therapies promoted by the emerging 
nanomedicine. This modern medicine is expected to provide techniques that can act 
on a cellular and even sub-cellular level, treating ailments with considerably more 
accuracy. 
Gradually, modern diagnostic and therapeutic techniques should elevate us 
slowly to the point where we can start thinking more in terms of real “regenerative” 
medicine. That means, we should be able to precisely and directly address 









Zur Trauer von Paul Ehrlich, dem bedeutendsten deutschen Immunologen, 
schrieb Kaiser Wilhelm II. in seinem Beileidstelegramm: „Ich beklage mit der 
gesamten gebildeten Welt den Tod dieses um die medizinische Wissenschaft und die 
leidende Menschheit so hochverdienten Forschers, dessen Lebenswerk ihm bei der 
Mit- und Nachwelt unvergänglichen Ruhm und Dank sichert.“ (Wikipedia 27. Mai 
2010) 
Mehr als hundert Jahre nach Ehrlichs Tod verfolgt die "Nachwelt" noch mit großen 
Schritten eine seiner wichtigsten Visionen, die er während seiner Arbeiten zur 
Behandlung der Syphilis entwickelte: eine „Zauberkugel“ (magic bullet), die einen 
gegebenen krankmachenden Erreger gezielt abtöten kann. 
Ganz nach diesem noch -mehr denn je- aktuellen Prinzip, entwickeln Forscher 
heutzutage weltweit neue Methoden, um nicht nur Krankheitserreger, sondern auch 
befallene Gewebe, spezifisch zu behandeln. In den letzten Jahren entwickelte sich 
dadurch die Medizin von der konventionellen Anwendung, über die personalisierte 
Behandlung, wo die genetische Information eines jeden Patienten präventiv 
untersucht werden kann und die Ergebnisse zur Auswahl und Anpassung der 
Therapie-Art herangezogen werden, bis hin zur "Nanomedizin", einer neuen Ära der 
Arzneimittel-Konzipierung, -Synthese, -Dosierung und -Verabreichung, die Therapien 
auf zellulärer und sub-zellulärer Ebene ermöglichen sollte. 
Mediziner sind heutzutage weit entfernt von der Darstellung von Christian Friedrich 
Hebbel (18.03.1813 - 13.12.1863), dass "ein Arzt eine Aufgabe hat, als ob ein Mensch 
in einem dunklen Zimmer in einem Buche lesen sollte". Sie sind in der Lage, durch 
die Integration der Nanotechnologie im biomedizinischen Bereich, Gewebe und 
Zellen, die durchschnittliche Dimensionen von 10 µm haben, mit Nanosystemen im 
Submikrometer-Bereich zu adressieren und gezielt zu behandeln. 
 
In diesem Rahmen präsentiert sich das Magnetic Drug Targeting (MDT) als 
besonders wirksamer Therapie-Ansatz. Dabei werden Wirkstoff-beladene 
magnetische Nanopartikel über externe Magnetfelder im Körper geführt und an 
einem gegebenen Krankheitsort lokal angereichert. Die verabreichte Wirkdosis wird 
dadurch erhöht, Nebeneffekte minimiert. Besonders in der Krebsbekämpfung 
verspricht dieser Ansatz hohe Erfolgsquoten und eine Reduzierung der ohnehin 
enormen Chemo- und Radiotherapie-Kosten, die meistens einen bremsenden Effekt 
auf die Entwicklung und Verbreitung zahlreicher Behandlungsmethoden haben. An 





Todesursache ist, an der schätzungsweise 11.5 Millionen Weltbewohner im Jahre 
2030 sterben werden, was einem Anstieg von 45% zum Jahre 2007 darstellt. 
 
Die zielgerichtete Arzneimittel-Applikation, zu Englisch "Directed Drug 
Delivery", soll hierfür Lösungen anbieten, die Tumore spezifisch angreifen und 
ausschalten können. Durch eine magnetische Lenkung und Anreicherung wird dieses 
Verfahren weiter optimiert. Die somit entstehende MDT-Methode eignet sich für 
Anwendungen in der Blutbahn, sowie in den Atemwegen von Patienten, mit 
entsprechenden Anpassungen. Entscheidend ist hierbei vor Allem das eingesetzte 
Magnetfeld, in Bezug auf Amplitude, Homogenität und Dynamik. In zahlreichen 
wissenschaftlichen Arbeiten, wurden bisher Erfolg versprechende Ergebnisse 
präsentiert, die überwiegend durch die Manipulation und Aufkonzentrierung von 
Nanopartikel-Wirkstoff-Komplexen mit statischen Magnetfeldern realisiert wurden. 
Eine hierzu komplementäre Betrachtung mit dynamischen Magnetfeldern wird in 
dieser Arbeit untersucht. 
Im Rahmen dieses Forschungsprojekts wurden Ansätze mit statischen und 
dynamischen Magnetfeldern zur Verbesserung des Magnetic Drug Targeting 
theoretisch überprüft, simulativ validiert und systemtechnisch umgesetzt. Nach 
einer ausführlichen Untersuchung der Nanopartikel-Eigenschaften, die den MDT-
Effekt überhaupt ermöglichen und besonders beeinflussen, wurde der 
Anreicherungsprozess unter Magnetkraftwirkung modelliert und ein für 
Anwendungen in der Blutbahn optimiertes Magnetsystem simuliert, konstruiert und 
bei in-vivo-Versuchen eingesetzt. Dadurch konnte eine aktive und vor Allem 
reproduzierbare Retention von beladenen Nanopartikel-Komplexen in den Arterien 
und Venen der Rückenhaut einer Maus verzeichnet werden. Analog zur Anwendung 
in den Blutgefäßen wurde anschließend das MDT in den Atemwegen untersucht. 
Hierbei wurden Magnetfeldrechnungen mit strömungsmechanischen Simulationen 
kombiniert, um das Verhalten von magnetischen Aerosolen im oberen Bereich der 
Lunge zu beschreiben und die entsprechenden Parameterwerte für deren 
gewünschte Sedimentation zu identifizieren. 
Es folgten in-vitro-Experimente in Kooperation mit dem Klinikum rechts der 
Isar, in denen gezeigt wurde, dass dynamische Magnetfelder die Effizienz der 
Einschleusung von Genmaterial ins Zellinnere (Transfektion) signifikant erhöhen. 
 
Die erzielten Ergebnisse, von der erreichten, theoretischen Verständnistiefe, 
über die gerätetechnischen Implementierungen, bis hin zur experimentell 
realisierten Steigerung der Therapieeffizienz in Targeting und Transfektion 
bestätigen das Potential des "Magnetic Drug Delivery"-Ansatzes und stärken die in 
den letzten 30 Jahren langsam gewachsenen Hoffnungen auf wirksamere und 






1 Background and Motivation 
Along with the progressive evolution from conventional to personalized 
medicine, hopes have emerged, that a further step towards more specific and 
efficient therapies can be achieved. Beyond treating patients in a differentiated way 
based on their individual responsiveness to drugs, which can be assessed through 
fine molecular tests or tests on relatives of the patient to establish hereditary 
(genetically determined) predispositions to certain diseases, it is believed that more 
selective methods even within an individual can be implemented. The most 
advanced vision of this vision is the concept of single-cell medicine, also termed 
“Nanomedicine”, which is gaining in importance and promising advanced medical 
interventions on cellular and sub-cellular or molecular level. 
Despite the continuous adaption and integration of great technologies into 
healthcare processes, the established traditional methods physicians currently 
follow to treat various maladies are still suboptimal, as they are very often based on 
rather coarse estimations. For instance, up scaling drug doses based on the weight or 
volume of patients is a standard medical method, completely lacking in precision or 
specificity (Sharyn D. Baker, 2002). In addition to that, nowadays’ therapies are rather 
meant to eradicate diseased tissues or cells and eliminate them. In doing so, the 
affected cells are forced to undergo necrosis, which is an induced death process 
where cells lose their membrane consistency and spill their content into the cellular 
milieu (Helmtrud I. Roach 1999). Considering the fact that cells naturally possess various 
ways to investigate and sample their environment by internalizing small quantities of 
the surrounding material found in the extracellular space and dissolving them, or the 
fact that cells are able to enclose and degrade dangerous intrusions, it becomes 
evident that cells dispose of powerful chemical substances (enzymes) and tools 
(lysosomes) to attack biological entities and disintegrate them (W. E. Walker 1968). 
These harmful agents are set free to the neighboring tissue, if the containing cells 
are damaged or caused to die in a different way than safe apoptosis (Tarl W. Prow 
2004).  It  then  quickly  comes  to  a  lack  of  chemical  signals  to  the  immune  system,  
which triggers a cascade of destructive events in the neighboring tissue. This leads to 
more damage, especially on the side of the still safe bystander cells. It is thus of 
great interest to pursue new methods through which a safer “switching off” or 
elimination of the diseased tissue is induced. This happens, when specific treatment, 
preferably in the same size range as cells and organelles, is achieved. For this 
purpose, submicron systems that are controllably synthesized down to the 5-10 nm 
range, and therefore approach even the size of single proteins, are needed for a very 





On account of this, next generation nanomedicine technologies are focusing 
on such nanosized tools and solutions capable of even detecting diseased cells, most 
importantly in tumoral tissues, infiltrating their cytomembrane and performing 
directed intracellular repair operations or triggering an apoptosis process (Marco A. 
Zarbin, 2010). 
Besides improved drug delivery, the introduction of nanobiotechnologies as well as 
nanoscale-structured machines and devices into medical practice generally holds 
great promise with regard to better diagnostics, transplantation procedures, better 
implants, real regenerative medicine, and minimally invasive surgery using 
nanorobots or in combination with adapted catheters (Jain, 2008). 
Especially in the field of treating cancer which is one of the leading causes of death 
in the developed countries, the nanotechnology based approach represents a 
promising tool to add more specificity to the ordinary treatment. 
As a matter of fact, standard chemotherapy which is one of the oncological 
treatments applied if the addressed tumors are not resectable can remarkably be 
improved and directed through nanosystems. Because it aims at delivering cytotoxic 
substances to the rapidly dividing cancerous cells in order to kill them, this 
systemically applied method also affects and harms other cells of the organism that 
are under normal circumstances fast-dividing. Due to this undesired side effect, not 
only cells of the bone marrow, of the lining of the digestive tract and in the hair roots 
are attacked, but also entire organs, mainly responsible for the circulation and 
filtration of blood, such as the heart, the liver and the kidneys, are damaged. 
 
By flooding the patient with chemotherapeutic drugs, clinicians achieve rather non-
significant to small effects, deploy a series of unwanted side effects that 
unnecessarily involve and stress the whole body, and cause exorbitant expenses in 
the healthcare system (Plank, 2009). 
In this scope, it is believed, that nanomedical systems would not only enhance 
treatment efficiency but also help minimize or even eliminate side effects and 
reduce costs. Srinivas et al mentioned that using nanotechnology in medicine can be 
an important complement to existing technologies and make a tremendous 
contribution to cancer detection, prevention, diagnosis, and treatment (Pothur R. 
Srinivas, 2002). Especially the early detection of tumors would help treat them more 
efficiently, before they undergo mutations and gain resistance to drugs. With regard 
to that, nanomaterials, such as quantum dots, gold nanoparticles, magnetic 
nanoparticles, carbon nanotubes, and gold nanowires, exhibit unique physical, 
optical and electrical properties that in combination with proteins, antibody 
fragments, DNA and RNA fragments which are the base of cancer biomarkers have 
proven to be very useful in cancer sensing and monitoring (Young-Eun Choi, 2010). For 
the treatment of cancer, nanosystems can be used as drug delivery devices where 





in question, or they can be utilized to heat up tumoral tissue or to perform gene 
therapy. For instance, over 100 drugs based on nanotechnology have been in 
development for the last years, with some having been already approved, e.g. Doxil 
(a liposome preparation of doxorubicin) and Abraxane (paclitaxel in nanoparticle 
formulation) (Jain, 2008). 
As shown in several studies (Jain, 2008), the most suitable nanosystem 
candidates to facilitate drug delivery and, more generally, achieve the goals of 
nanomedicine are multilayered nanoparticles. These are submicron beads having at 
least one dimension ranging from 1 to 100 nm and exhibiting size-dependent 
physical (optical, electrical or magnetic) and chemical properties remarkably 
different from those of bigger samples made of the same materials. It is here 
noteworthy, that the radical change in properties is just a natural result of the 
matter being shrunk to nanoscale. 
 
In fact, just by attentively observing nature and its “natural nanoparticles”, 
like viruses, it becomes quickly obvious that modern science has to mimic these 
structures to have access to a toolbox on cellular and organelle scale, without 
causing severe interference with the organism (Benyus 1997) (Salata 2004).  It  is  even  
believed that nanoparticles can interact with the components of cells such as cellular 
membranes and nucleic acids which are nanometer in scale (Pascal R. Leroueil, 2007). 
 
Nanoparticles have been intensively studied and developed over the last few 
decades, especially as biodegradable carriers for drug delivery applications. The 
carried therapeutics can be entrapped, adsorbed, attached, dissolved or 
encapsulated into the nanoparticle, leading also to new constructs, such as 
nanospheres and nanocapsules. Depending on the form used, the release process of 
the transported biological agents varies. The advantage of these nano-scale objects 
is, first, that they are small enough to penetrate deeper porous structures in the 
organism such as smaller capillaries and even cell membranes. When taken up by 
cells, they can deposit their load in the intracellular milieu and assure an efficient 
drug accumulation at target sites. Their small size, if precisely controlled, gives them 
furthermore sharp optical properties so that they can act as very efficient 
fluorescent probes, for example by emitting narrow light (Salata, 2004). Second, the 
coating of nanoparticles with appropriate biodegradable materials allows not only 
for biocompatibility but also for a controlled and slow release of the carried drug, as 
many cancer treatments require that only the targeted organ receives the drugs at a 
pre-programmed rate and at well-defined concentrations (Sanjeeb K. Sahoo, 2003). 
Therefore, it is very important to have nanoparticles with tightly controlled, narrowly 
distributed sizes and accordingly engineered coatings. 
But size and hull  are not the only problems.  In  fact,  having tackled and solved the 





nanosystems within the body and to have them perform the intended tasks with 
precise  mechanisms  of  action  at  the  relevant  sites.  This  is  achieved  by  passive  or  
active targeting. In passive targeting, the nanoparticle coupled to the therapeutic 
agent passively reaches the target organ by making use of the enhanced permeation 
and retention effect (EPR) involving the fast growth of tumoral blood vessels that are 
in consequence porous and abnormally fenestrated  (Wayne L. Monsky, 1999). This way 
of passing pores and cell membranes is however nonselective and based only on size 
criteria (Pascal R. Leroueil, 2007).  Active  targeting,  in  the  contrary,  is  achieved  by  
conjugating the carrying nanoparticle or the carried drug to a cell or tissue-specific 
ligand that only binds at the target site (ALF LAMPRECHT, 2001).  As  a  complement  to  
these methods, there has been gradual interest in the last years to investigate and 
introduce a further targeting technique, involving magnetic nanoparticles that can 
be magnetically directed to target sites. 
1.1 Magnetic nanoparticles in medicine 
Besides nanorods, nanotubes (Sang Jun Son, 2005), nanowires, cylindrical and 
plate-like shaped nanoassemblies, which are all nanosized structures and constructs 
used in biology and medicine, spherical nanoparticles represent the largest category 
of biomedical nanosystems (Salata, 2004) (Jain 2008). These are solid or colloidal 
particles consisting of macromolecular substances and having a diameter that ranges 
from  a  few  to  250  nm  (Torchilin 2006). Their spherical shape is often intrinsically 
defined through the synthesis process and is most suitable for loading additional 
layers to the particulate, such as functional groups, and for meticulous operations 
such as pore passing and cell penetration. Nanoparticles are used in a variety of 
biomedical applications, especially as fluorescent biological labels thanks to their 
protein-like size making them suitable for bio-tagging and labeling, bio-detection of 
pathogens and proteins, tissue engineering, separation and purification of biological 
molecules, drug and gene delivery  (Hongwei Gu, 2006),  cancer therapy, or as contrast 
enhancers for medical imaging, such as gold nanoparticles in x-ray imaging  (AuroVist, 
2009) or superparamagnetic iron oxide nanoparticles (SPIONs) in magnetic resonance 
imaging  (Claire Wilhelm, 2008)  (Hyon Bin Na, 2007). Evidence has also been furnished that 
nanoparticles, if drug-loaded and conjugated to the surfaces of therapeutic cells, 
could enhance cell therapy (Matthias T Stephan, 2010).  But  in  most  cases,  the  
nanoparticle is used as a carrier of a bioactive load and therefore acts as an effective 
drug delivery device. In order to selectively detect the target and securely interact 
with its biological entities, a nanoparticle should bear a molecular or biological 
coating consisting of functional layers, sensing extremities and a biocompatibility 
envelope. Figure 1 depicts the composition of a typical nanoparticle system used in 





various functional molecules. 
 
In the context of nanomedicine and its approaches for directed therapy, fitting 
nanoparticles with additional magnetic properties presents a further feature that 
dramatically enhances their ability to specifically target entities in the body. Systems 
comprising such an "intelligent" particle core enable the possibility of addressing, 
distally guiding and concentrating drug carriers through external magnetic fields. 
Combined with a receptor recognition layer and a therapeutic load, such a 
nanoengineered device can be considered as the tool of the future with the highest 
potential for therapeutic applications. 
 
 
Figure 1: Composition of a standard nanoparticle system for biomedical applications (adapted 
from (Salata 2004)) 
1.1.1 Manufacturing: 
Nanosized materials can be obtained by two approaches. When opting for a 
top-down technique, bulk material is gradually made smaller through physical 
processes including crushing, grinding and milling. Larger particles are thus broken 
up into smaller entities, until the nanoscale is reached. 
In the bottom-up approach, the nanosized material is built starting from the 
atomic level by wet phase chemistry and defined sizes are reached by stopping the 
corresponding chemical reaction at exact times to freeze the particle growth process  
(Halim, 2008). 
Magnetic nanoparticles usually consist of components exhibiting magnetic 
properties, like iron oxides (such as Fe3O4 and y-Fe2O3), pure metals (such as Ferrum 
















The most important and established methods of magnetic nanoparticle 
synthesis are: 
 Co-precipitation 
A simple and efficient technique to build iron oxides through adding a base to 
an aqueous Fe2+/Fe3+ salt  solution  at  room  temperature  (or  above)  and  under  
conditions of inert atmosphere  (An-Hui Lu, 2007). 
 Thermal decomposition 
Heat is used to cause chemical decomposition of organometallic compounds 
into monodisperse magnetic nanocrystals. This is achieved in the presence of organic 
solvents and stabilizing surfactants. Shape and morphology of resulting crystals are 
mainly controlled through the ratios of the used reagents, reaction temperature and 
time (An-Hui Lu, 2007). 
 Microemulsion 
As microemulsions are stable dispersions of two liquids, they can be used to 
synthesize nanoparticles through precipitation caused by the addition of solvents 
such as ethanol or acetone. The resulting nanoparticle-precipitate can be isolated 
through centrifugation or filtering. Examples of particulates obtained by 
microemulsion are gold-coated cobalt/platinum, metallic cobalt and cobalt/platinum 
alloys (An-Hui Lu, 2007). 
 Hydrothermal synthesis 
Magnetic nanoparticles, in particular iron oxides, can also be synthesized by 
oxidation of iron containing chloride compounds in basic aqueous solutions under 
elevated pressure and temperature (Song Ge, 2009)  (Yuhong Mi, 2006). 
 
The different synthesis methods for magnetic nanoparticles are depicted in Table 1, 
with an emphasis on the major factors of feasibility and scalability. 
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For biomedical applications, magnetic nanoparticles are generally fabricated 
along  "bottom-up"  processes,  starting  from  atoms  or  molecules  and  growing  the  
nanostructures in a controlled way (Arruebo Manuel 2007). Such particles commonly 
consist  of  a  metal  or  metallic  oxide core serving as  magnetic  element such as iron,  
nickel and cobalt and their chemical compounds. As a synthesis technique, co-
precipitation is most used, as it is a very efficient and easy to scale-up process. 
Theoretically, all magnetically addressable components can be used to 
fabricate magnetic nanoparticles for clinical use. Moreover, the general rule applies 
that the stronger the responsiveness to magnetic attraction, the better the control 
over the particulate. This led scientists to the use of cobalt and pure iron, or alloys of 
iron, platinum, cobalt and carbon to synthesize particles showing strong reaction to 
magnetic fields and higher saturation magnetizations (Jana Chomoucka, 2010). However, 
a major problem related to these materials refrained clinicians from applying them 
in biomedical purposes. For instance, cobalt is highly toxic and pure iron is hyper-
sensitive to oxidation, which imposes the encapsulation of particulates made of 
these materials in inorganic coatings to prevent or minimize toxicity or oxidation, 
respectively. Due to these constraints and with regard to the simplicity of their 
synthesis, iron oxide magnetic nanoparticles have advanced to the status of the most 
commonly used magnetic nanoparticles. Superparamagnetic magnetite (Fe3O4) and 
maghemite ( -Fe2O3) can easily be fabricated through physical or chemical 
processes, and are under controlled conditions totally bio-compatible (Torchilin, 2006). 
Precipitation of Fe(II)/Fe(III) hydroxide in an inert atmosphere, followed by 
adequate stabilization  (Mykhaylyk Olga, 2007), produces magnetite particles that are 
easily dispersible in water, having generally ellipsoidal shapes and sizes between 3 
and  30  nm  with  a  size  distribution  of  10  to  20%   (Torchilin, 2006).  Similar  to  the  
established industrial techniques available to use and manipulate magnetic 
nanoparticles in suspensions, such as in audio speakers/boxes or magnetic 
separation for the purification of industrial water (Franzreb, 2003), the obtained iron 
oxide nanoparticles can be sorted to narrow their size distribution to about 5%  
(Torchilin, 2006). 
When used clinically, magnetic nanoparticles need to meet all necessary 
biocompatibility criteria and have to fulfill their biomedical purpose. For that, special 
coatings have been developed assuring non-toxicity, stability and molecular 
reactivity, and thus enhancing physical and chemical properties of the nano-systems. 
Additionally, magnetic interaction between particles imposes the intercalation of 
layers encapsulating the single beads and avoiding unwanted agglomeration. To 
incorporate this concept, modern techniques to synthesize magnetic nanoparticles 
are mostly based on a core/shell structure. The core being the iron oxide 
component, the shell represents its coating and enables better dispersion and 





should however be brought to size, as the total diameter of the particulate should be 
below 100 nm to avoid fast clearance by the reticuloendothelial system (RES). 
The surface coating of magnetic nanoparticles is achieved through layers of 
polymers, proteins, silica or other organic and inorganic materials (dextran, starch, 
polyethylene glycol (PEG), polyvinyl alcohol (PVA), gold, etc.) (Jana Chomoucka, 2010)  
(Torchilin, 2006). In a layer-by-layer building approach, the nano-system is then 
enrobed in further functionalization (i.e. anchoring of biofunctional molecules onto 
the nanoparticle) shells protecting it from degradation and enabling its activation 
and bio-interaction capabilities (An-Hui Lu, 2007).  
1.1.2 Biomedical applications of Magnetic Nanoparticles: 
Magnetizable nanoparticles present highly interesting properties allowing for 
multiple medical and biological applications. For instance, researchers use MNPs for: 
 cellular and macromolecular separation processes (bioseparation), where target 
cells or molecules labelled with nanoparticles are isolated from a mixture with high 
specificity and sensitivity (José Luis Corchero, 2007)  (Hongwei Gu K. X., 2006) 
 contrast enhancement in diagnostic and interventional imaging, especially 
magnetic resonance tomography, where the MNPs used are saturated in the scanner 
field and create a perturbing dipole that shortens the T2 relaxation time of protons 
more that T1, thus contributing to the contrast of the acquired image  (Pankhurst Q A, 
2003). 
 magnetically mediated hyperthermia, where magnetic nanoparticles that are 
exposed to an alternating magnetic field are heated to reach temperatures above 
43°C,  thus  selectively  destroying  cancer  cells  that  are  more  sensitive  to  heat  than  
healthy tissue. This selective inducting heating of targeted regions in the body might 
imply other fabrication techniques for the nanoparticles (José Luis Corchero, 2007) 
(Torchilin, 2006). 
 arterial embolization therapies where nanoparticles are used to block blood 
vessels and delay tumor growth or inhibit tumor angiogenesis 
 gene transfer and therapy, where magnetic nanoparticles are used to introduce 
foreign genetic material into target cells, thus increasing the expression of a given 
gene or allowing for genetic engineering operations (José Luis Corchero, 2007) 
 for targeted drug delivery and release, especially in cancer treatment, where 
drugs associated to magnetic nanoparticles are brought to accumulate at a desired 
site in the organism under magnetic focusing, thus enabling higher concentrations of 
bio-active substances at targeted tissue locations (Torchilin, 2006) 
 
In these application fields as well as the newer developments of magnetic 
nanoparticle usage, the administration of the nano-systems occurs systemically via 





or directly through injection into diseased organs or tumor tissue  (Arruebo Manuel, 
2007), as well as over inhalation (oral administration) to the inner parts of the lungs. 
 
1.2 Magnetic Drug Targeting (MDT) 
"Was mich nicht umbringt, macht mich stärker" 
("That which does not kill me makes me stronger") 
Friedrich Nietzsche (1844 – 1900), Sprüche und Pfeile, 8. 
 
Despite the enormous advances made in the development of pharmaceuticals 
and novel drug delivery methods, the demand for more efficient and financially 
bearable treatments for a multitude of disorders, like cardiovascular diseases, 
ailments of the respiratory and nervous system as well as tumors, is still present and 
expected to grow  (Sanjeeb K. Sahoo, 2003). Normal ways of administrating drugs imply a 
uniform distribution of that drug in the body of the treated patient as it is injected in 
the blood and systemically delivered to all vascularized organs. This inevitably leads 
to the pharmaceutical substance distributed at other sites than the therapeutic site, 
which   decreases the efficiency of therapy, raises treatment costs -as a larger drug 
quantity is required to deliver the needed effect at target site- and may cause toxic 
side effects at healthy tissue level (Yokoyama, 2005). Especially in chemotherapy, these 
limitations are observed and represent a major challenge to reach full treatment 
success. 
In fact, tumors can quickly develop drug resistance and if treated in a sub-
optimal way, remaining tumoral tissue can rebuild to a more resistant malignancy, 
imposing therefore a change in the therapy strategy. Moreover, the organism 
irreversibly changes after it is treated with a given medicine, so that it will not react 
to further drugs the way it would have done before alteration. Each and every 
administration of a new therapeutic substance has an impact on the responsiveness 
of the organism to the next steps of a medication plan. Therefore, any drug therapy 
should be planned and carefully conducted till the complete elimination of the 
ailment. 
With regard to these challenges, Magnetic Drug Targeting (MDT) has emerged 
as a concept of concentrating drugs at therapeutic sites through binding them to 
magnetic nanoparticles that are guided in the body and retained via external 
magnetic fields. Especially for tumor treatment, holding the chemotherapeutic agent 
at the desired site of activity significantly increases therapy efficacy and reduces side 
effects mainly observed as systemic toxicity (Torchilin, 2006). 
The principle of Magnetic Drug Targeting has been examined and tested in-vitro and 





most relevant results have been so far the successes achieved by Widder et al. in 
1979 when they reported a 200-fold increase -compared to systemic intravenous 
administration- in the concentration of the chemotherapeutic drug doxorubicin 
retained at a targeted tumor area in a rat’s tail. They had opted for an intra-arterial 
application (Sophie Laurent, 2011).  In  1981,  the  same  group  also  achieved  a  complete  
tumor remission in 77% of a colony of Yoshida rats having sarcomas in their tales 
(Torchilin, 2006). Many research groups followed and reported successful applications 
in hamsters, rabbits and swine.  In 1996, Lübbe et al. successfully treated tumors in 
mice and rats through an intravenous injection of 100 nm sized magnetic 
nanoparticles coated with anhydroglucose linked to 4-epirubicin (an analog of 
doxorubicin with similar anti-tumor activity but significantly lower cardiotoxicity). 
They used a magnetic field of 0.2-0.5 T and achieved significant drug accumulation at 
target-site. The injected nanoparticles landed finally mostly in liver and spleen, and 
only minor amounts deposited in heart, lung and kidney. Also in 1996, Lübbe et al. 
reported a first phase I clinical trial involving 14 patients with squamous carcinoma 
(a cancer of a kind of epithelial cell) of the breast or head and neck. They received 
intravenous injections of 4-epirubicin coating 100 nm ferrofluidic particles and were 
exposed,  at  the  relevant  target  regions,  to  a  0.5-0.8  T  magnetic  field  for  60-120  
minutes. The drug accumulated in the tumor area in six patients with no rejection. 
Systemic effects were reduced and toxicity was lower than after 4-epirubicin 
treatment alone (Challa S.S.R. Kumar, 2005). MRI examination revealed, however, that 
more than half of the magnetic nanoparticles landed in the liver (Torchilin, 2006). 
In 2000, Alexiou et al. successfully treated New Zealand White rabbits with 
implanted experimental squamous carcinoma in the hind limb. Magnetic 
nanoparticles bearing mitoxantrone were intravenously (ear vein) and intra-arterially 
(femoral artery) injected and retained at tumor site through external magnetic fields, 
resulting thus in complete and permanent remission of the tumor (Christoph Alexiou, 
2000). Further successful studies in rabbits (R Jurgons, 2006) and hamsters (Kubo T, 2001) 
have also been reported in 2006 and 2001 respectively. 
It is at this stage also noteworthy to mention the positive results reported by the 
company FeRx in 2000 and 2002 and indicating a successful use of carbon-coated 
iron particles bearing doxorubicin and having diameters of 0.5-5 µm in a clinical trial 
targeting inoperable liver cancer cells. Here too, therapy-related toxicity has been 
reported as very low (Torchilin, 2006). 
 
Despite the differences in nanoparticle-drug-complexes used, the magnetic 
systems applied and the various ways of administration chosen in these studies, a 
common denominator for Magnetic Drug Targeting in the blood vessels remains the 
need for an accessible tumor that is enough vascularized and irrigated by blood, in 
order to allow nanoparticles to reach it. It is also a challenge to appropriately tune all 





of MDT treatment depends on the nanoparticle properties and behavior, the 
magnetic field, and the blood flow conditions. 
In a relevant literature note, the specifications of a successful setting indicate a 
needed high magnetization of the MNPs in order for them to be sufficiently 
addressed by the external magnetic field and overcome linear blood flow rates of 10 
cm/s in arteries and 0.05 cm/s in capillaries. Nanoparticles should also fulfill 
biocompatibility requirements, exhibit sizes below 200 nm, anti-agglomeration 
behavior as well as a long circulation capability (Challa S.S.R. Kumar, 2005). Kumar et al. 
also suggest the used magnetic field has to have a magnetic flux density of at least 
0.8 T for nanoparticulates featuring 20% of magnetite. For the majority of 
nanobeads, this density might be as low as 0.2 T but with a field gradient of 8 T/m 
for arterial application. The maximum depth that can be reached is, in that case, 8-
12 cm (Challa S.S.R. Kumar, 2005). 
In fact, the weak magnetic fields generated by the available systems result in a 
restriction of the applications of magnetic drug targeting. For instance, the limited 
depth reached by the magnetic field makes it rather impossible to treat ailments at 
tissues or organs deep inside the human body. Therefore, MDT -as it is allowed by 
the available magnet technology- is more suitable for pathologies near the surface of 
the  body,  where  a  magnetic  system  is  easily  placed  and  the  distance  to  the  
transportation pathways through which particles flow is minimized. Examples for 
these diseases which are treatable under similar circumstances are surface tumors 
like prostate and breast cancers or skin malignancies. 
But depth is not the only challenge facing MDT. Putting aside the potential 
hazard of nanoparticle dislocation to lungs and brain, if MNPs passed the blood-brain 
barrier, major issues still remain at the level of the particles, their stability, their 
magnetic responsiveness, toxicity, drug conjugation, magnet technology, and flow 
control. Another crucial point is the effect of “mis-targeting” which leads mainly to 
the damage and loss of “innocent” bystander cells, and in the most severe cases 
enables non-linear reactions of the organism that are very hard to contain or to 
counter. 
The need for concentrating and intelligently guiding the therapeutic effect is 
therefore obvious and becomes more important if we additionally consider avoiding 
the  costly  drug  wastage  related  to  systemic  application.  This  is  exactly  the  area  of  
activity of MDT which should be further developed to allow for solutions that enable 









1.3 Magnetic drug targeting in the lungs 
Just  as  magnetic  drug  targeting  makes  use  of  the  natural  –and  in  case  of  
tumors modified- vasculature and blood circulation to efficiently deliver 
chemotherapeutics to specific compartments of the organism, it is intuitively 
imaginable to expand this “nanotechnology approach to drug delivery” to other 
circulation systems in the body, for instance, to the respiration system. This has led 
in the last years to the exploration of a new area of MDT, the so called “Lund Drug 
Targeting (LDT)”. The idea behind it is simply to apply the experiences and results 
gained from magnetic drug targeting in the blood vessels to assure a local treatment 
of pulmonary diseases (Dames, 2007). 
 
This application of MDT gains in importance when we recall the fact that lung 
cancer causes the death of 1.3 million people worldwide, representing thus the most 
fatal cancer type for men and the second deadliest for women (Dahmani Ch., 2008). 
Lung drug targeting emerges here as a promising technique to treat carcinomas in 
the lungs, by delivering drugs through the pulmonary ways directly to the tumor 
sites in the trachea and bronchial tree over actively loaded superparamagnetic 
nanoparticles. These particles are encapsulated in aerosols and guided by external 
magnetic fields. 
 
It is here noteworthy to mention that aerosol application –on which LDT is 
based- is an established, non-invasive route of drug delivery to deep pulmonary 
compartments, mainly to the alveoli, and which is routinely used in the medical 
treatment of many diseases such as asthma, COPD or mucoviscidose (Gonda, 1990) (G. 
Scheuch, 2006). This is mainly due to the fact that delivering medications by inhaling an 
aerosol has intrinsically important advantages over systemic drug delivery, such as 
the direct deposition of medication to airway receptor sites, the fast onset of action 
of the deposited drugs, the lower systemic bioavailability of medications 
administered via inhalation and the ease and convenience of self-administration by 
patients. Furthermore, aerosol-based drug delivery allows for lower medication 
dosages and thus for cost reduction, while achieving the desired therapeutic effect. 
Making use of these same advantages, the intratracheal administration route is 
nowadays being intensively evaluated for tumour healing (L.  W.  Wattenberg,  2004)  (Y.  
Zou, 2007). 
 
LDT  successes  have  been  reported  by  P.  Dames  et  al  in  2007,  when  they  
showed in a simplified computer-based simulation of a theoretically elaborated 
concept,  and  in  experiments  performed  on  mice,  that  targeted  aerosol  delivery  to  
the lung is feasible, with aerosol droplets that contain superparamagnetic iron oxide 





over  100  T/m  and  spherical  aerosols  of  3.5  µm  comprising  MNPs  with  a  50  nm  
diameter (Dames, 2007). 
 
In 2005, Ally et al demonstrated –based on an in vitro model- that magnetically 
targeted deposition of aerosols presents a feasible, potential technique to treat 
cancers of the lungs (Javed Ally, 2005). 
 
Despite the evidences brought to our knowledge through these results, it can 
be easily noticed, that works done to explore LDT so far, still involve too simplified 
models, be it experimental or simulative, and achieved findings in an animal model 
that cannot be automatically extrapolated to human application. 
 
Additionally to these limitations, several other aspects of LDT -of technical and 
clinical relevance- present important challenges and deserve thorough investigation.  
For instance, due to the strong dependence on the respiration flow, the exact 
reproduction of a given drug distribution in the lungs remains a principal issue and 
makes automatic comparisons of achieved results relatively complex. This is but just 
one simple example of the issues related to fluid dynamics that will be encountered 
while studying LDT. Moreover, the magnetic parameters have to be compliant with 
the particularities of steering magnetic nanoparticles in the inhaled air. The range of 
the magnetic field is with respect to this the most relevant aspect and airborne 
particles have to be addressed within the lungs, over distances usually inaccessible 
to externally applied magnetic forces, which implies the need for stronger magnets 
capable of generating greater field gradients. The steering is also difficult as 
treatment of ailments in the lungs might involve just one defined compartment of 
the respiration tract, making accurate particle guidance necessary to concentrate the 
therapeutic effect on the relevant pathways. Further synchronization of the 
magnetic and respiration activities is furthermore crucial to optimize nanoparticle 
retention efficacy. 
 
Provided targeting and particle deposition have been successfully achieved, 
further challenges emerge as to the need for surmounting or avoiding the clearance 
mechanisms in the lungs and assuring a clinically efficient uptake of the applied 
drugs. 
 
Finally, just as it is important to pre-interventionally simulate and plan the lung 
drug targeting procedure, it is also crucial to monitor and assess its outcomes. These 






1.4 Chapters overview 
The  purpose  of  this  work  is  to  investigate  the  most  relevant  among  the  
currently explored aspects of guiding drug-loaded magnetic nanoparticles in the 
body to achieve loco-regional targeted therapeutic effects. Hereby, both the 
application in blood vessels and in the pulmonary airways will be addressed. 
After a thorough introduction laying the ground for a primary understanding of these 
two clinical applications and the motivation behind investigating them, chapter 2 will 
outline the nanoparticle properties relevant for a successful magnetic drug targeting, 
including toxicity and transportation aspects. 
In chapter 3, the application of MDT in blood vessels will be examined, with a 
focus on magnet technology and experimental validation on animals. 
The primary concern of chapter 4 will then be to explore the transition to the 
application in the pulmonary airways, covering simulative evaluations as well as 
technical and experimental aspects. Once results from both fields are presented, the 
common challenge of internalizing the retained drug-bearing nanoparticles at target-
site will be tackled and constitutes the core of chapter 5. 
Finally, in the sixth section, further relevant aspects related to the monitoring 
and evaluation of therapy progress, as well as imaging challenges in MDT will be 
covered, before results are discussed in the final chapter. 





2 Nanomagnetism and further relevant properties of 
magnetic nanoparticles 
2.1 Magnetism at the nanoscale and related MNP properties 
With  the  lecture  he  gave  in  1959  at  the  yearly  meeting  of  the  American  
Physical Society at the California Institute of Technology (Caltech), entitled „There’s 
plenty of room at the bottom”, the physicist Richard Feynman ignited the 
exploration of small-scale materials and inspired the concept of nanotechnology 
(Feynman, 1992). Since then, nano-scaled systems have been the focus of a continuous 
attention, intensively studied and investigated. 
The driving force behind this interest lies in the innumerable possibilities 
enabled through the properties of nanomaterials that gain even further 
attractiveness when it comes to magnetic nanomaterials. 
For magnetic drug targeting, nanosized, magnetically active particulates are used 
(MNPs). As these usually have an iron oxide core, they are often referred to as 
superparamagnetic iron oxide nanoparticles (SPIONS). 
To understand how these particles, when they reach the nanoscale, exhibit 
extraordinary properties that totally differentiate them from bulks of the same 
materials, it is crucial to investigate the impact of size reduction on the surface area-
to-volume ratio. 
In fact, in a bulk crystal, the majority of the atoms are located in the inner part 
of the volume occupied by the crystal. The number of atoms within the volume 
exceeds by far the number of atoms on its surface. These inner atoms define –thus- 
the properties (physical, chemical, electrical and optical) of the bulk material. 
As the size of the crystal is reduced, the surface area-to-volume ratio increases, and 
the influence of the atoms comprised in the surface of the material surpasses the 
contribution of the inner atoms to the definition of the crystal properties. This is due 
to the resulting larger contribution of the surface energy to the overall energy of the 
whole system, decreasing so the impact of the inner bulk atoms on the properties of 
a material (Halim, 2008).  
The increasing importance of surface atoms in nanosized matter is shown in 






Figure 2: Relationship between the percentage of surface atoms in a particle and its size (Halim, 2008) 
 
This clear “surface effect” is not the only aspect dominating the magnetic properties 
of  MNPs.  It  is  also  endorsed  by  “finite-size  effects”  that  give  rise  to  the  special  
feature of superparamagnetism which is the major property of nanoparticles making 
them suitable for magnetic drug targeting. 
2.1.1 Superparamagnetism: 
Magnetic materials owe their properties to their microstructure, comprising 
primarily magnetic domains and the transition regions between these domains –the 
so-called magnetic domain walls-. A magnetic material exhibits under certain 
conditions these domains which are regions within the material showing uniform 
magnetization: this means that in that compartment the individual magnetic 
moments of the atoms are aligned with one another and pointing in the same 
direction. 
Due to energetic constraints, a magnetic material spontaneously divides into 
separate domains. In fact, through avoiding a state with a magnetization in the same 
direction all through the material, internal energy is minimized. 





significant magnetic field reaching outside of the material volume and storing a large 
quantity of the magnetostatic energy. When the considered sample splits into two 
domains, with the magnetization of each of them in the opposite direction of the 




Figure 3: Minimizing magnetostatic energy stored in the external magnetic field of a material 
sample through the creation of internal magnetic domains. The magnetic field lines extend in 
loops in opposite directions through each domain, which reduces the field outside the material 
(Dutz, 2008). 
 
To  further  minimize  the  field  energy,  each  of  the  two  domains  can  split  into  
smaller parallel domains with magnetization in alternating directions, exhibiting thus 
smaller amounts of field outside the material. 
For magnetic nanoparticles, there exists, nevertheless, a critical size below which it 
costs  more  energy  to  create  a  new  domain  and  a  new  domain  wall  within  the  
particle than to support the magnetostatic energy of the single-domain state. In that 
case, the MNP comprises a single domain (O'Handley, 2000). 
This threshold size depends on the nature of the material and typically is about a few 
tens of nanometers (An-Hui Lu, 2007). For Fe-based nanoparticles, a single-domain 
structure is expected at sizes below 25 nm (Arruebo Manuel, 2007). 










Table 2:  Selected materials and the corresponding critical sizes below which they display a single-
domain structure (An-Hui Lu, 2007) 
Material Critical diameter in nm 
Co (hcp shaped) 15 










In magnetic nanoparticles with single domains, the dimensions are so small that the 
thermal energy becomes of the same order of the magnetic energy and the spins are 
increasingly affected by the thermal fluctuations. As a result of these thermal 
fluctuations, the direction of magnetization varies randomly, similarly to the 
direction of the magnetic moments of atoms or ions in a paramagnet which varies 
under the action of thermal motion. As a consequence, the system of nanoparticles 
behaves, in magnetic fields and under temperature changes, like a paramagnetic 
material of N atoms (N being the number of NPs). The spin of each particle being 
free to fluctuate in response to thermal energy, the resulting coercive field is 
substantially equal to zero and the material exhibits no remanence, which leads to 
an anhysteretic B H curve as shown in Figure 4. 
The nanoparticles in this state are said to be superparamagnetic. In this state, 
the magnetic moment can reorient in times less than 1 ns due to thermal agitation 
(Sibnath Kayal, 2010). 
In summary, superparamagnetic NPs are highly magnetized in the presence of an 
external magnetic field, but their magnetization disappears as soon as the magnetic 




Figure 4: Hysteresis loops for ferromagnetic and superparamagnetic nanoparticles, in comparison 






Msat = Saturation magnetization
Mr = Remanence magnetization





In the work presented here, superparamagnetic nanoparticles based on iron 
oxide cores have been used. For the most important experiments in this study, 
namely the targeting in blood vessels and the transfection enhancement, so called 
PEI-Mag2 NPs have been selected. These are core/shell-type magnetite 
nanoparticles where the core has an average crystallite size of about 9 nm; their 
surface is coated by the fluorinated surfactant Zonyl FSA (lithium 3-[2-
(perfluoroalkyl)ethylthio] propionate) combined with 25-kDa branched 
polyethylenimine –a type of water soluble polymer- (PEI-25Br). The hydrodynamic 
diameter of the particles in aqueous suspension is 28 ± 2 nm. The presence of PEI in 
the surface layer of the PEI-Mag2 particles results in a highly positive net -potential 
of the particles when measured in aqueous suspension (+55.0 ± 0.7 mV). The 
saturation magnetisation per unit of iron weight at 298 K is 62 emu/g or A·m²/kg iron 
(Mykhaylyk O. A., 2007) (Mykhaylyk, Steingötter, Perea, Aigner, Botnar, & Plank, 2009). 
 
Parameter Value 
Phase composition of the core Magnetite 
Mean crystallite size of the core <d> in nm 9 
Saturation magnetization of the core Ms (A·m²/kg of iron) 62 
Average iron weight per particle (g of iron per particle) 1.4 x 10-18 
Effective magnetic moment of the particle Meff (A·m²) 8.7 x 10-20 
Iron content (g of iron / g of dry weight) 0.56 
Stabilizer content (g of stabilizer / g of dry weight) 0.23 
Mean hydrated particle diameter in water Dh (nm) 28 ± 2 
Electrokinetic potential in water,  (mV) +55.0 ± 0.7 
Shell composition PEI-25Br (32 mass %) 
ZONYL FSA (68 mass %) 
Table 3: Relevant properties of the PEI-Mag2 magnetic nanoparticles 
 
The magnetic moment of the PEI-Mag2 nanoparticles -and of every 
nanosystem used under magnetic locomotion- is of critical importance. It describes 
the magnetic response of the carriers to an imposed external magnetic field and 
induces the movement and migration of the particle loaded with bioactive substance 
in the blood, air or intracellular space. 
Magnetic moments can be described using two models: magnetic poles and atomic 
currents. In the classical definition of magnetic moments, these are vectors pointing 
from  the  south  (theoretic)  pole  to  the  north  pole  of  a  magnetic  dipole  and  
characterizing its general magnetic properties. The local value of the magnetic 
moment per unit volume is then defined as the magnetization of a magnetized 
material (J. Stöhr, 2006). 





responsiveness has been evaluated (Mykhaylyk, Steingötter, Perea, Aigner, Botnar, & Plank, 
2009). H441 cells have been loaded with the PEI-Mag2 MNPs and the obtained 
assemblies have been exposed to a uniform magnetic field gradient of 4 T/m. 
As depicted in Figure 5, two sets of 4 Ne-Fe-B permanent magnets have been 
placed on both sides of an optical cuvette in a spectrophotometer containing the cell 
suspension. The labelled cells are attracted in a direction orthogonal to the magnets. 
A light beam is propagated through the cuvette, perpendicular to the trajectory of 
the cell movement. The intensity of this light that can be sensed at a point behind 
the suspension becomes greater as more cells are pulled to the surface of the 
recipient and turbidity is diminished. The time course of the normalized turbidity of 
the magnetic transfection complexes is evaluated to determine the magnetophoretic 
mobility of the MNP-labelled cells through calculating the magnetic responsiveness 
in µm/s and the average magnetic moment of the cells. 
 
 
Figure 5: Measurement of the magnetic responsiveness of the magnetically labeled cells and the 
magnetic nanoparticles 
 
The motion of MNPs in a magnetic field gradient obeys the formula 
 
=  ( 1 ) 
 
As derived in (Leach, 2003). 
 (Am²)  is  here  the  total  magnetic  moment  of  the  complex  containing  the  
nanoparticles, calculated as the product of the effective magnetic moment, , of 
a single particle and the number N of MNPs attached to a given cell ( = ). 
 (T or Vs/m²) is the magnetic flux density. 
Based on the measurement of the clearance kinetics in the evaluated cell 





the magnetic field gradient is determined and the number of particles associated 
with a cell can be calculated (Mykhaylyk, Steingötter, Perea, Aigner, Botnar, & Plank, 2009). 
At this stage, it is noteworthy to also consider two further properties of the NP: 
2.1.2 The zeta potential 
The Zeta ( ) potential of a nanoparticle in a colloidal solution is the potential 
difference between the dispersion medium, i.e. the particle, and the stationary layer 
of fluid attached to the dispersed particle. It is therefore an indicator for stability in 
colloidal dispersions, as it shows the extent of repulsion between neighbouring 
particles bearing the same type of charge in a solution. A high zeta potential makes 
colloids of small size stabilized and resistant to aggregation. For the used PEI-Mag2 
suspension in water, the zeta potential was determined as +55.0 ± 0.7 mV by Photon 
Correlation Spectroscopy (PCS) using a Zetasizer, which sufficiently stabilizes the 
particles against aggregation. 
2.1.3 The Cluster Theory 
As the magnetic properties and behavior of MNPs in the magnetic drug 
targeting applications are decisive aspects to successfully conduct a therapy, it is of 
great importance to understand the mechanisms exerting an influence on 
magnetically guided samples of particles. Magnetic interactions are therefore to be 
continuously evaluated before using the nanocarriers. 
In the applications we are investigating in this work, mainly two types of interactions 
are interesting: the dipole-dipole interactions and the direct exchange interactions 
for touching particles (An-Hui Lu, 2007).  As  has  been  described  in  (Gleich, 2007), the 
overall magnetization of a number of MNPs in high concentration under the 
influence of an external magnetic field can be higher than the sum of their individual 
magnetic moments. This is explained by the Cluster theory. This means that loaded 
nanoparticles can exhibit the phenomenon that their ability to follow the magnetic 
field and their responsiveness to the external magnetic forces increase non linearly 
with the number of involved nanoparticles. This suggests nonlinearity in the resulting 
total magnetic properties of the samples. 
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where M is the magnetization of the MNP and is a function of the magnetic flux 



















MBM  ( 3 ) 
    
(with Ms saturation magnetization, k Boltzmann constant, T temperature, B magnetic 
flux density and dequ the diameter of the core of each particle) 
Yet every magnetized particle generates a magnetic field that can be written to 






rµrµrµzyxB  ( 4 ) 
 
(where µ  is  the  magnetic  moment  of  the  particle,  µ0 = 4 ×10 7 V·s/(A·m)  is  the  
vacuum permeability and r  is the vector pointing to the point in space in which the 
magnetic field is evaluated) and can contribute to the magnetization of the 
neighboring particles. Each particle would then experience a contribution Bj to its 
magnetization, generated by the neighboring n particles (assumed the system center 
is at the origin of the considered coordinates system and the z axis is pointing in the 






















MM  ( 5 ) 
 
Mi is the resulting magnetization of a given nanoparticle surrounded by n neighbors. 
  
To investigate this effect, a simplified measurement setup that precisely 
determines the total magnetic moment of different nanoparticle samples has been 
conceived, based on a high precision balance and a strong permanent magnet. The 
developed method allowed the measurement of the magnetic force on different 
nanoparticles’ charges and shapes, and therefore the deduction of their total 







                 
 
Figure 6: Measurement setup to determine the total magnetic moment of a given nanoparticle 
charge (left), Nanoparticle suspension exposed to magnetic force for magnetic moment 
measurement (right) 
For a suspension of nanoparticles in an inhomogeneous magnetic field, at a point in 
space with a known gradient, the mass displayed on the high precision balance is 
directly proportional to the magnetic moment of the suspension 
=  
 
As a direct consequence of the Cluster effect, a measurement of the cooperative 
behavior of a nanoparticle sample shows a nonlinear increase in its total magnetic 
moment with increased mass. Figure 7 depicts this effect for a sample of FeSi MNPs. 
 
 
Figure 7: Nonlinear increase of the total magnetic moment of a sample with augmented sample 






Now, having described these important aspects of particle-particle interactions, it is 
necessary to mention that in most cases, the effect of “Cluster Theory” is negligible, 
especially in constellations where the NPs are treated in a suspension: 
- as the nanoparticles usually reach their saturation magnetization when fully 
exposed to the used magnetic fields (> 100 mT), for instance within a volume of 
2x2x2 mm³ around the magnet tip. A particle within this area is fully magnetized and 
cannot benefit from the contribution of the neighboring particulates. 
- as the zeta-forces stabilize the colloidal solution by sufficiently repelling the MNPs 
from each other. 
For our calculations in this work, neglecting the magnetic particle-particle 
interactions is a worst case scenario (Gleich, 2007) as the real resulting magnetization 
of a given sample of MNPs is higher than the assumed one, given the fact of mutual 
magnetization when the applied magnetic field is below saturation level. 
One further property that is often used to tune nanoparticles and optimize their 
behavior in an MDT environment is their shape.  
2.1.4 The nanoparticle shape 
The morphology of a nanoparticle is crucial for determining its behavior in 
industrial and especially medical applications. A change in the shape of a NP can 
cause an important change in its electromagnetic properties and with regards to 
biological interactions (Yuhong Mi, 2006). In particular, the magnetic properties of 
MNPs can be significantly tuned through shape arrangement. Furthermore, 
nanoparticles having modified designs –e.g. allowing them to exhibit a larger 
surface- are able to attach significant quantities of biological agents (T.K. Indira, 2010). 
Among others, researchers from the Johns Hopkins and the Northwestern 
universities have demonstrated in animal tests that a modification in a 
nanoparticle’s shape could dramatically affect its efficacy in delivering gene therapy 
to cells (EurekAlert, 12 Oct 2012). 
Although spherical nanoparticles are being used in most applications, there is a 
pertinent advantage in modifying this conventional shape to reach improvements in 
surface functionalization and environmental compatibility of the nanocarriers (Sang 
Jun Son, 2005). 
Additionally to general observations made about nanoparticulates of non-
spherical forms (Torchilin, 2006), the use and evaluation of spindle-type nanoparticles 
have also been reported in the literature (Yuhong Mi, 2006).  To assess the usability of 
this particular shape in the experiments conducted in this study, nanoparticle 
samples (FluidMAG/SP-D 100nm) manufactured by the company Chemicell have 
been provided in a size range of 100 nm and exhibiting an elongated spindle shape. 





solution to facilitate its binding to the wafer surface resulted in particle 
agglomeration that could not be visualized through microscopy. A further attempt 
involved the dilution of the fluidMAG/SP-D particulates in alcohol (pure 
isopropanol). A sample of the obtained solution was then spin coated on a silicon 
wafer covered through sputtering by a 3 nm titan layer and a 2 nm layer of gold. The 





Figure 8: SEM images of spindle shaped nanoparticles after spin coating on a silicon wafer and 
sputtering (titan + gold) - top-left: a fluidMAG/SP-D particle/ top-right: two adjacent fluidMAG/SP-
D particles/ bottom: the sample comprising multiple nanoparticles whereas their particular shape 
was lost through processing for SEM imaging. 
 
The nanoparticles were then visualized using a Scanning Electron Microscope 
(SEM). Figure 8 depicts the images obtained through SEM and shows the loss of 
shape due to the processing of the sample through spin coating and sputtering. 
This observed low stability against mechanical stress, added to the special 





the major arguments that led to the use of spherical magnetic nanoparticles in the 
further experiments of this research work. 
2.2 Toxicity Vs. biocompatibility 
Since the first uses of magnetic nanoparticles in the medical field, researchers 
have been evaluating and addressing their safety aspects. Interestingly, the small 
size of the nanomaterials, which is the main advantage leading to their successful 
integration into healthcare applications, is at the same time the major source of 
uncertainties with regards to the unintended effects of their use. In drug delivery for 
instance, nanoparticles present an enormous potential because they can be driven 
within the body to organs and tissues that usually aren’t accessible through classical, 
bigger carriers. Yet, exactly this ability might represent a threat to a patient’s health 
if the nanoparticles cannot be controlled in the organism. This is described as the 
toxicity of nanocarriers (Jain, 2008). 
This toxicity can be related to several factors (Arruebo Manuel, 2007): 




 coating (surface chemistry) 




 way of administration 
 
Toxic effects of particulates in the body, either introduced through implants or 
aerosolized solutions, have been intensively studied, but the results and the amount 
of evidence reached are still non exhaustive. Further investigations will be needed. 
The statement that can be made is that nanoparticles can be entirely safe, and can 
also exhibit forms of toxicity. This usually leads to the necessity of a risk-benefit 
evaluation and trade-off. Nevertheless, several properties contributing to the 
biocompatibility of nanoparticles have been identified and tuned in different studies.  
 
As  a  matter  of  fact,  the modification of  the surface chemistry remains an essential  
tool to minimize toxicological effects –as it defines how the particle is going to 
interact with the surrounding tisuue-, followed by the surface-to-volume ratio that 
can be controlled to avoid unfavorable biological responses. Sizes of less than 50 nm 





But even this observation becomes relative when we consider magnetic 
nanoparticles, for which it has been reported that larger particulates show higher 
cytotoxicity than smaller ones, when administered in concentrations in the range of 
20-100 mg/ml (Arruebo Manuel, 2007). At this point, it is noteworthy to recall that the 
cytotoxiciy of a given nanosystem reflects its toxic effects on single cells, usually 
measured by the determining the concentration of the said substance that leads to 
the death of 50 % of a cell culture within 48h (Jain, 2008). 
 
The measures that need to be taken to prevent unintended toxicological 
processes during application range from a safe bionanomanufacturing technique to a 
stringent immune surveillance after injection (Marco A. Zarbin, 2010), endorsed by the 
conduction of an adequate number of tests before applying the nanoparticles to the 
used  animal  model  or  patient  body.  Tests  generally  assess  acute  and  long  term  
toxicity, as well as the potential to stimulate inflammatory reactions. Through these 
checks, drug delivery nanoparticles should prove their non-toxicity and non-
immunogenicity. They also have to fulfill hematocompatibility (compatibility with 
blood and blood cells), given the fact that most of the nanoparticles are led to 
tumors in the body through the bloodstream. 
Further safety aspects are directly related to the route of administration that plays a 
major role with regards to the fate of the nanoparticles in the body, during and after 
application. 
For instance, intravenous administration presupposes that the used 
nanocarriers are not only nontoxic and non-immunogenic, but also small enough to 
prevent embolizing capillary ducts or any other occlusion of the vascular system (R 
Jurgons, 2006). A nanoparticle injected into the blood is quickly subjected to the 
process of opsonization which consists in covering it with plasma proteins (e.g. 
immunoglobulins). This way, the nanoparticle is exposed to the recognition by the 
RES (reticuloendothelial system) defense mechanism that involves highly phagocytic 
cells derived from the bone marrow. The RES enables mononuclear phagocytes or 
monocytes to clear and deliver the trapped nanoparticles to the liver (Kupffer cells), 
spleen, lymph nodes and bone marrow. The phagocytosis and clearance of the NPs is 
performed in 0.5 to 5 minutes (Challa S.S.R. Kumar, 2005), removing thus the 
nanocarriers from the circulation and preventing them from accessing the target 
site,  usually  tumor cells.  Depending on their  size,  the NPs may be delivered to the 
bile and excreted in the feces or filtered by the kidneys and incorporated into the 
urine.  A general observation suggests that smaller nanoparticles are rapidly 
removed by renal elimination whereas larger carriers are taken up by the liver, 
spleen and bone marrow. In Table 5, the different removal processes and cells 








Particle characteristic removal process involved cells 
Large phagocytosis macrophages or dendritic cells 
Small Endocytosis B or T lymphocytes 
(biodegradable) magnetic NPs Pinocytosis any cells 
Table 4: Different removal processes of NPs (Arruebo Manuel, 2007) 
 
In  the  special  case  of  magnetic  particles,  sizes  of  up  to  4  µm  lead  to  an  
elimination through the cells  of  the RES,  mainly  in  liver  (60-90 %) and spleen (3-10 
%), sizes of more than 200 nm to a filtering by the spleen, and sizes below 100 nm 
mainly to phagocytosis by liver cells. The latter observation can for instance be used 
for treating liver tumors and diseases. It has also been reported, that smaller 
particles exhibit longer plasma half-life-times, i.e. that they circulate for much longer 
in the blood. Figure 9 summarizes the different cases of distribution and the routes 
taken by NPs after their injection into the body. 
 
 
Figure 9: Fate of nanoparticles after injection for cancer therapy (Challa S.S.R. Kumar, 2005) 
 
In  general,  it  can  be  said  that  in  order  for  a  nanoparticle  to  accomplish  its  
mission within the organism, it has to fulfill the key requirement of biodegradability 
or intact excretion. To ensure the latter in the case of nonbiodegradable cores, a 
specific coating can help avoid the exposure of the core until the excretion is assured 
by the kidneys. But even if the used material is biodegradable, an appropriate 
coating is needed to mask the NP from the clearance systems of the body so that it 
remains in blood circulation for a longer time. 
When retained at target site, nanoparticles do not access the tumors through normal 
tissue, but use the hyperpermeable vasculature to enter and accumulate in the 
tumor interstitial region. There, the intrinsic lack of lymphatic clearance in tumoral 





When biodegraded, the NP releases the drug load in the interstitium and the 
bioactive substance can then be absorbed into the tumor cells through diffusion. 
 
As mentioned before, for Magnetic Drug Targeting applications, iron oxides 
with a core/shell structure are the most widely used nanoparticles. In particular, 
magnetite (Fe3O4) and maghemite ( -Fe2O3) are preferred over other materials 
because of their biocompatibility and nontoxic character (Jana Chomoucka, 2010). Cobalt 
and Nickel do have better magnetic properties, yet they present a great hazard of 
toxicity and are therefore not suitable for human application. 
Iron oxide is considered to be biologically safe, for it is easily degradable. When used 
in in-vivo applications, SPIONS are metabolized into elemental iron and oxygen by 
hydrolic enzymes. The iron is stocked in the normal body stores and is slowly 
embedded into hemoglobin through normal biochemical pathways known for iron 
metabolism. It has not been reported that iron oxide nanoparticles caused any 
toxicity effects such as alteration of the renal function, hepatic parameters, serum 
electrolytes or lactate dehydrogenase. The natural elevation of the iron level in the 





Figure 10: Dependence of the blood residence time of NPs on their size (Arruebo Manuel, 2007) 
 
No side effects related to the use of iron oxide particles have been reported in the 
literature (Challa S.S.R. Kumar, 2005). This can be easily verified through the number of 
contrast agents based on magnetic Fe oxides available on the market (e.g. Feridex®, 





systems (e.g. FluidMAG®, TargetMAG®). All satisfy the US regulations for use in 
human patients (Arruebo Manuel, 2007). 
As already generally noticed for nanosized carriers, the time an iron oxide 
nanoparticle spends circulating in the blood also highly depends on its size. This is 
illustrated in Figure 10. 
 
As implied above,  there are still  other aspects  of  toxicity  to be considered in 
order to establish a fully safe therapy based on magnetic nanoparticles. In fact, 
toxicity can also be achieved by using iron oxide nanoparticles in an unbalanced 
concentration. In that case, the nanocarriers would represent no threat for cells as 
single particles but can as a group hinder the cells in their normal functioning 
through blocking its communication and interaction with its environment. Thus, a 
given nanoparticle type might be intrinsically nontoxic, but when applied in 
overdosed concentrations, it is susceptible to disturb the bioactivity of a targeted cell 
causing decrease in its vialbility. 
Additionally, nanoparticles with particularly small sizes can cross the blood-brain-
barrier  (BBB)  and  access  the  inner  compartments  of  the  brain.  An  effect  that  can  
easily develop potential for malignancy. In a similar way, nanoparticles can be 
transferred from a mother to the fetus across the placenta and can constitute a 
danger for fetal cells.  
On the other hand, it might be apparently controversial, but it is exactly the effect of 
toxicity that is needed to eliminate tumor cells in cancer therapy. Yet this has to be 
“controlled toxicity”, i.e. the nanoparticles have to go through a safe voyage in the 
organism, land at target site and then deploy “useful toxic” effects in the therapy 
area. 
 
Finally, if we extrapolate the notion of toxicity to cover all hazards of the MDT 
therapy, further aspects can also be considered, especially the magnetic field and its 
impact on organs, living tissue and bioactivity. In fact, the magnetic fields used in 
MDT have to be very large in order to produce significant effects.  This  suggests  an 
assessment of the interaction of strong, static and dynamic magnetic fields with cells 
and cell communication and viability. Yet, sufficient clinical and safety experience 
has shown that the prudence and reserves towards magnetic fields reported in the 
1980ies were misplaced and, for instance, the US Food and Drug Administration 
(FDA) revised the threshold set initially for allowed magnetic field values from 2 T in 
1987 to 8 T (for adult patients) in 2003. No clinically relevant observation could be 
made  about  the  capacity  of  large  magnetic  fields  to  reduce  blood  flow  velocity  or  
affect the behavior of erythrocytes containing micrograms of the Fe protein 
hemoglobin (Arruebo Manuel, 2007).  Gradually, evidence is also being established 
regarding the use of dynamic magnetic fields in the low frequency range interesting 





surely far below critical values susceptible to generate hyperthermia effects or the 
uncontrolled triggering of action potentials in nerves (Dutz, 2008). 
 
2.3 More efficient transport systems in MDT 
Despite the superparamagnetic property of most of the nanoparticles used for 
magnetically guided drug delivery, it is still a great challenge to achieve sufficient 
retention at the target site when applying free particles. This is particularly due to 
the strong flow of the medium in which the drug carriers are navigated, be it blood 
or air. To increase magnetic responsiveness and therefore retention, magnetic 
nanoparticles can also be combined into larger conglomerates exhibiting a significant 
overall magnetic moment (Torchilin, 2006).  Assuming  that  special  care  is  paid  to  
interparticle interactions, concentration and homogeneity of the resulting magnetic 
properties, nanoparticles are assembled to stable structures, either by conjugation 
into complexes comprising the bioactive load and the biocompatibility agents 
(Mykhaylyk, Steingötter, Perea, Aigner, Botnar, & Plank, 2009) or by aggregation into larger 
compounds (encapsulation). Figure 11 shows as examples for this approach a 
schematic  view  of  a  complex  used  in  gene  delivery  and  a  conglomerate  of  single  
nanoparticles. 
 
     
 
Figure 11: Left - Schematic illustration of an DNA-MNP-Enhancer complex comprising 110000 particles and 
47000 plasmid copies as described and used in (Mykhaylyk, Steingötter, Perea, Aigner, Botnar, & Plank, 2009), 
Right – a conglomerate of magnetic nanoparticles (FluidMAG-D) from the company Chemicell® as visualized 
under scanning electron microscopy 
 
Following  the  same  principle  of  magnetic  moment  consolidation,  the  use  of  
further sophisticated structures such as microbubbles has been reported. These 
consist in small gas filled cavities stabilized by a lipid, protein (albumin) or polymer 
layer. For applications in blood, the used gas has to exhibit low solubility. 





particularly iron oxides- tightly bound or incorporated into their membrane, the 
nanoparticles being associated with different genes, siRNA, drugs or 
oligonucleotides. The obtained structures have sizes ranging from nano- to 
micrometers, and show favorable magnetic properties and a high binding capacity 
for nucleic acids. 
This combination of microbubbles with their ability to enhance image contrast 
in ultrasonography and iron oxide nanoparticles with their high magnetic 
susceptibility and biocompatibility has already been exploited to create dual-
modality contrast agents for both ultrasound and magnetic resonance (MR) imaging 
(April M. Chow, 2010) (Wen He, 2012). Coupling these two components helps overcome 
the issues of non-stability specific to microbubbles and the problems of non-specific 
penetration related to nanoparticles (Cai X., 2012). Using the same association in 
Magnetic Drug Targeting applications is therefore a logical evolution, and comes 
along with several advantages. For instance, encapsulating a great number of MNPs 
in the shell of a microbubble improves its magnetic properties and enhances its 
responsiveness to external magnetic fields, contributing thus to a better magnetic 
navigation and to a more precise targeting effect. This precision is enhanced when 
exploiting the fact that the membrane of a microbubble can be burst through 
exposure to ultrasound. By appropriately application, it can be achieved that only 
insonated target areas are affected by drug release and subjected to therapy. 
A similar enhanced efficiency has also been reported by using magnetic lipospheres 
(Dialechti Vlaskou, 2010), a structure assembled through the shaking of a mixture of a 
cationic lipid, a nucleic acid, magnetic nanoparticles, aqueous buffer, and soybean 
oil. These lipospheres not only produce contrast in ultrasound images, they also 
exhibit higher magnetophoretic mobility resulting in an increased magnetic retention 
effect, in comparison with lose nanoparticles. Experiments conducted with these 
carriers led to functional DNA and siRNA delivery in vitro. 
 
The  same  effect  is  also  exploited  when  applying  MDT  for  lung  and  airway  
therapy, where aerosols are enriched with great numbers of magnetic nanoparticles 
to create structures that exhibit higher magnetic responsiveness than single 
particulates. Further advantages of this combination are controlled delivery and 
release through magnetic guidance and activation, associated with the ability of 
performing CT and MR imaging (e.g. when using magnetite, gold nanoparticles or 
organic compounds) and the capacity to reach deep compartments of the lungs. 
Furthermore, the amount of drugs that can be loaded into a structure like aerosols is 








3 Magnetic guiding of nanoparticles for drug targeting 
in the blood vessels 
In this chapter, the application of Magnetic Drug Targeting in blood vessels will 
be examined, starting with a model to describe the controlling variables and their 
interactions in the process of in-vivo magnetic guidance of nanoparticles, followed 
by a focus on the used magnet technology and leading to the experimental 
validation in animal models. 
3.1 Modeling and Magnet 
3.1.1 Modeling the MDT process 
Several models have been reported in the literature to describe and eventually 
predict the mechanisms involved in magnetic drug targeting, in the blood as medium 
as well as in the airways. The common principle to all these models is the property of 
magnetic fields to exert forces on matter. 
In the case of magnetic nanoparticle complexes, this force is described through the 
formula (1) introduced in chapter 2.1 
 
=  
In  the  microvasculature  surrounding  a  target  site,  e.g.  a  malignant  tumor  areal,  a  
nanoparticle carrying a therapeutic load is subjected to various forces ranging from 
the magnetic attraction, to the hydrodynamic and drag forces, over gravity and 
floatation or buoyancy. A schematic illustration of the most influential of these 
factors is depicted in Figure 12. 
 
To describe the medium in which the nanoparticles are navigated, it is 
essential to have a close look at its components. Blood, for instance, consists of red 
blood cells, white blood cells, platelets and approximately 55 % of plasma.  Red cells 
are the largest among the constituents and the most numerous, therefore prevailing 
in defining the mechanical properties of blood. In comparison, white cells and 






Figure 12: Schematic illustration of major forces acting on a magnetic nanoparticle navigated in 
blood vessels 
 
At  the  normal  shear  rates  observed  in  vessels,  blood  is  assumed  to  be  a  
homogeneous incompressible Newtonian fluid of viscosity 0.003 – 0.004 kg/m·s at a 
temperature of 37°C. This means that its viscosity coefficient is independent of the 
velocity  gradient.  In  large  blood  vessels,  the  flow  is  said  to  be  a  “plug  flow”  and  
exhibits more uniformity. In capillaries and smaller blood vessels, the flow has a 




Figure 13: Front shapes of a plug flow (top) and a parabolic flow (bottom) in large and small blood 






Considering the conditions and assumptions at hand, fluid motion in blood vessels 
can be described using the Navier-Stokes equations. These comprise three velocity 
equations and the continuity equation: 
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Where u, v, w are velocities in x, y, z direction respectively,  is the fluid density,  its 
viscosity, p is the pressure, gx, gy, gz are the components of  the gravitational  force 
field in x, y, z. The variable t represents time and u is the velocity vector. 
Solving this equation system goes through reducing it to time dependency: 
 
= + ² ( ) p ( 10 ) 
 
Here,  is a volume force field and represents other external body forces (M. Lohakan, 
2007), for instance a magnetic force. 
Using this equation, the hydrodynamic forces exerted on a nanoparticle submerged 
in an incompressible fluid can be determined (Thomas Weyh, 2004). Hereby, it is further 
assumed that for capillaries, hydrodynamic interactions between particles and 
vessels can be neglected, which is true when the diameter of the particle is much 
smaller than the diameter of the vessel. Additionally, steady flow conditions can be 
assumed as the calculated Reynolds number for the submerged particle in motion 
within the fluid is fairly small (Ovidiu Rotariu, 2005). 
In fact, though the Reynolds numbers will be presented in detail in chapter 4.2, 





of µm/s and the dimensions of the geometry below 100 µm, Reynolds numbers of 
less than one are often obtained. 
This leads to the formulation of the hydrodynamic drag force acting on the 
nanocarrier as given by Stokes formula (Ovidiu Rotariu, 2005) 
 
= 3  ( 11 ) 
 
Where  is again the viscosity of the medium (here blood),  the hydrodynamic 
diameter of the particle and its velocity. 
Considering the small size of the nanoparticles, we further assume that gravity and 
inertia (drag) forces are negligible compared to magnetic and hydrodynamic forces, 
so that a condition can be deduced to retain the nanoparticle and pull it to the 
magnet tip 
 ( 12 ) 
 
Having (11) this condition can be translated into 
 
 
 ( 13 ) 
 
Assuming a reduced model of the problem in only two dimensions, all involved 
quantities can be described based on two unit vectors. The extrapolation to a 3-
dimensional coordinate system is then easily implementable. 
The Stokes force is re-written to  
 
= 3  ( 14 ) 
And the parabolic profile characterizing the flow velocity in small vessels, e.g. 
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Assuming that the magnetic moment of the particle is aligned with the external 
magnetic field, this magnetic moment of one single nanocarrier can be re-written to  
 
=  ( 16 ) 
 
with  =  and  =  
The magnetic force on a particle is therefore 
 
 







 ( 18 ) 
 
When the particle is magnetically pulled within the flow towards the vessel wall, a 
magnetic force in the y-direction (perpendicular to the flow) is acting on it and is 
counterbalanced by a drag force governed by Stokes law. 
 
, = 3  ( 19 ) 
 
where  is the viscosity of the medium (here blood),  the hydrodynamic diameter 
of the particle and the velocity of the particle in the y-direction. 
With the condition (12), this leads in the worst case to 
 
, = 3  ( 20 ) 
and thus to  
 
= ,3  






The time needed for a particle to reach the vessel wall under these conditions and 
departing from the vessel centerline is (assuming is not time-dependent) 
 
=  ( 22 ) 
On the other hand, the particle is exposed to the magnetic field only in a constrained 
area surrounding the magnet tip for which a length L should be assumed. To cross 
this length, a particle flowing along the centerline of the vessel needs a time  
 
=  ( 23 ) 
 
The time t needed to reach the vessel wall has to be less than  
 
 ( 24 ) 
 
With (22), this leads to  
 
 ( 25 ) 
and thus to 
 
, 3  ( 26 ) 
 
Combining this result with (18) implies 
 
+ 3  ( 27 ) 
 
This condition on the needed magnetic field can be numerically computed, or –with 
the further assumption that the magnetic flux density is approximately fully defined 







 ( 28 ) 
 
Similarly, a condition on the magnetic field gradient in the x-direction can be 
obtained through considering reduced hydrodynamic forces acting on the particle 
when it reaches the vessel wall (Bernhard Gleich, 2007). 
 
In practically all models, a quantitative evaluation is achieved only through 
numerical simulation, where the values of the governing quantities are computed 
using a combination of solvers for magnetostatics (involving the Finite Element 
Method) and computational fluid dynamics (CFD) (M.  Lohakan,  2007)  (Ushka  K.  
Veeramachaneni, 2007). 
Based on calculations and experimental investigation performed by the research unit 
within which this thesis has been elaborated, the minimal value required for 
magnetic flux density is set to be above the saturation magnetization of the 
nanoparticles used in the corresponding experiments, for instance higher than 200 
mT, whereas the field gradient should reach values above 10 T/m (C. Alexiou, 2006). 
Other scientific papers suggest values between 200 and 700 mT for the magnetic flux 
density and between 8 T/m and 100 T/m for the field gradient (P.A. Voltairasa, 2002), to 
achieve a magnetic effect in deeper tissue, whereas further investigations of 
magnetic targeting in models led to significantly lower values for the necessary 
gradient ranging from 0.03 to 10 T/m (Shin-ichi Takeda F. M., 2006). 
 
3.1.2 The magnet 
To perform the in-vivo experiments intended in this part of the thesis, a strong 
electromagnet exhibiting specific features has been designed and constructed. 
 
The design of the electromagnet was based on the specifications deduced in 
chapter 3.1, with the ability to produce the necessary magnetic field properties in an 
active volume of 2x2x2 cm³, which covers the whole volume of a small tumor area in 
a laboratory mouse model including its microvasculature. The entire system was 
conceived in a way to be manageable and of small size. 
 
Prior to construction, the electromagnet was simulated using the simulation 
software COMSOL Multiphysics to investigate the optimal shape and physical 
parameters assuring the availability of a minimum magnetic flux density of 200 mT 





To compute and plot the magnetic flux density around the system tip, the model of 
the  electromagnet  was  implemented  in  2D  as  well  as  in  3D.  Since  the  problem  is  
symmetric  to  the  z-axis,  it  was  adequate  to  use  the  2D  axial  symmetric  mode  in  
order to reduce complexity and processing time. For geometry visualization and 
construction purposes, a 3D model has also been revolved out of the 2D outline. 
 
The simulation was conducted based on the Maxwell equations, where Maxwell-
Ampere’s law for the magnetic field (A/m) and the current density  (A/m²) 
applies: 
 
× =  ( 29 ) 
 
For the magnetic flux density , Gauss‘ law states that 
 
= 0 ( 30 ) 
 
With the constitutive relation between  and  reading 
 
=  ( 31 ) 
 
Where µ0 is the magnetic permeability of vacuum (Vs/(Am)) and µr is the relative 




Introducing a magnetic vector potential obeying 
  
= ×  And = 0 ( 32 ) 
 




× =  ( 33 ) 
 
thus, reducing the basic input parameters to the relative permeability of the yoke 
material and the external current density. 
 
 
Through optimizing the simulation results, the parameters have been determined as 







Diameter of the copper wire d = 1.2 mm 
Cross-section of the wire Al = 1.13 mm2 
Average length of the winding lm = 34.56 cm 
Number of windings N = 3714 
Length of the coil l = 1283.56 m 
Mass of the coil m = 12.95 kg 
External current density J = 1.79e6 A/m² 
Relative permeability r = 4·10³ (Iron) 
Output voltage U = 41.12 V 
Output current I = 2.04 A 
Power loss P = 83.71 W 
Adiabatic heating  = 40.3 K 
 
Table 5: Parameters for the coil simulation 
 
The final design comprised an iron yoke and an optimized tip geometry, as well 
as a adequately dimensioned copper coil. The iron yoke was necessary to enforce 
the magnetic flux density. The magnet system was designed in a modular way 
allowing for adjustments of the air gap between tip and yoke basis within a range of 
3 to 7 cm and for the replacement of the tip, enabling, thus, the adaptation of the 
electromagnet to different sets of experimentation. Figure 14 shows the geometry of 











The simulation allowed the computation of the magnetic flux density in and 
surrounding the electromagnet, as well as the magnetic field gradient. Figure 15 
shows the B-Field generated by the magnet system and the orientation of the field 







Figure 15: Simulated magnetic flux density of the designed electromagnet (top), and plot of arrows 
symbolizing the magnetic field lines surrounding the magnet tip (Hoke, 2008) (I. Hoke, 2008) 
 
For  a  total  current  of  2.04  A  applied  to  the  coil,  the  magnetic  flux  density  
directly under the magnet tip was calculated to 588 mT. With the distance from the 
tip, the flux density falls then rapidly. The field gradient ranges from 27.08 T/m for z 











Figure 16: Plot of the magnetic field density and gradient with distance from the magnetic tip 
 
 
After successful simulation, the electromagnetic system was constructed, based on 
the dimensioning plans displayed in Figure 17. The material used for all components, 
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Figure 17: construction plans for the electromagnet, with a modular assembly design and an 
adaptable tip arrangement 
 
 
The coil winding was performed using a 1.2 mm thick copper wire, and the variable 
air gap realized through a screw thread concept in the upper part of the yoke 
permitting the exchange but also an infinitely adjustment of the tip level. Figure 18 









Figure 18: Constructed experimental electromagnet, with its exchangeable tip system (bottom) and 
after assembly (top). The top left figure shows the magnet after galvanization and featuring a 
temperature measurement strip. 
 
To prevent corrosion, the different components of the magnet were galvanized. 
Furthermore, 2 constant voltage generators (50 V/ 5 A) arranged in series were used 
to supply the system, delivering in total a voltage of 100 V and a current intensity of 
5 A. 
 
Finally, a thermal analysis was conducted through simulation showing an 





temperature of  the winding,  whereas the filling factor  of  0.5 to 0.6 of  the coil  was 
not taken into account during calculation which can therefore be considered to be a 
worst case estimation of the thermal behavior of the system. To closely monitor the 
real time heating of the coil during experimentation, a reversible temperature 
measurement strip was mounted on the outer coil surface. 
 
3.2 Animal experimentation and results 
3.2.1 Targeting of microbubbles to the cutaneous blood vessels of a 
mouse (the in vivo application) 
Whereas working with mathematical and simulation models or even cell lines 
is usually marked by a straight forward realization and reproducibility -including 
manageable difficulties during implementation-, experiments in vivo remain the 
most delicate part in research work, but also the most significant in terms of 
transferability to clinical application. 
 
To explore and gather evidence about the efficiency of magnetic drug 
targeting, experimental work has been conducted in the scope of this thesis, 
involving pre-clinical trials on laboratory mice. This work was supported by the team 
of Prof. Dr. Krötz at his Physiology Institute, at the Medical Polyclinic of Munich. 
 
The magnet system described in chapter 3.2 was used to realize microbubble 
retention in the blood vessels of the skin of a mouse. The choice of applying 
microbubble structures was based on first observations within the research activity 
that the retention of single, lose nanoparticles carrying oligonucleotides was not 
possible in the used model, therefore, a more efficient carrier structure was needed, 
as already explained in chapter 2.3. 
 
The final goal of the experiments was to explore the site specific gene delivery 
in the vasculature of the skin through actively and selectively trapping magnetic 
nanoparticles carrying a therapeutic load at the target site. 
 
To best expose the blood vessels in the specified area of the back skin of the 
mouse, a dorsal skin-fold chamber model was used, allowing additionally for 
visualization of the skin vasculature while keeping the animal alive, as shown in 
Figure  19.  One  major  advantage  of  the  chamber  is  that  it  can  remain  mounted  on  








Figure 19: The dorsal skin-fold chamber model, where part of the dorsal skin of a laboratory mouse 
is stretched along the window of a fixing device, allowing the visualization of the vasculature as 
well as the exposure to strong magnetic fields 
 
The fixation chamber further fulfills the requirement that the targeted blood vessels 
are fully participating in the circulation. Interestingly, the used cylindrical Plexiglas 
cage does not impair or compromise the vital functions or calmness of the mice, as 
they are usually used to living in small structures and tight environments. 
Animal selection: 
Although male mice are more robust and likely to survive after the different 
manipulations needed to mount the skin-fold chamber, they present specific 
drawbacks consisting mainly in the biting scars they bear on their dorsal skin due to 
territorial fights with their male rivals as well as the strong pigmentation of their skin 
significantly compromising the visibility of the blood vessels in the chamber device. 
Therefore, female mice might be more appropriate for the presented investigation. 
However, it is necessary to reach a statistically correct observation and validation of 
the MDT effect, which imposes considering both genders in equal proportions for 
these experiments. 
8 males and 8 females were involved in the study. 
Animal preparation: 





narcosis one day before exposure, by implanting a micro-catheter (seen in yellow in 
Figure 17) into their carotid artery in order to have access to the blood circulation. 
This manipulation is highly delicate, as the dimensions of the blood vessels are 
exceptionally small and the catheter has to be accordingly shaped and further shrunk 
in size through heating. For the number of mice prepared, only 50% of them survived 
this intervention and participated in the study. 
In a first step of the experimentation, only the trapping effect was investigated. For 
this, nanoparticles were coated with fluorescent oligonucleotides and incorporated 






Figure 20: Flipped arrangement of the magnetic system with the upwardly oriented tip, allowing 






The layout of the magnetic system was transformed based on its modular 
design, by reversing the direction of the magnet tip and flipping it on top of the iron 
yoke, as displayed in Figure 20. 
 
This arrangement allowed an optimized placement of the magnet tip under the 
dorsal skin-fold chamber (starting from a distance of 1 mm), as shown in Figure 21 





Figure 21: Fixation device including skin-fold chamber mounted on top of the magnet tip 
 
The solution featuring the microbubbles loaded with the PEI-Mag2 
nanoparticles as well as a GFP-enriched viral shell containing no DNA material was 
then injected into the catheter and brought into circulation with the blood of the 
mouse. 
 
Through this injection (150 to 200 µl), the total blood volume ranging from 1.5 to 2 
ml  and  flowing  in  the  whole  vasculature  of  the  20-30  g  animal  is  dramatically  
augmented (~ 10 %). This is comparable with adding 750 to 1000 ml of fluid to the 
human blood volume, comprising normally 7 l, within only 20 minutes. Therefore, it 
was not feasible to subject the mice to a second injection during one experiment and 
the effect was investigated in one single application. 
 
To keep the mouse under control and therefore avoid artifacts in experimental 
results or images, narcotizing substances were used, yet without altering the blood 







For a qualitative assessment of the targeting efficiency, optical verification 
under intravital microscopy was assured by placing the entire dorsal skin-fold 
chamber under an Axiotech Vario microscope (Zeiss, Göttingen, Germany) and 
visualizing the fluorescence expressing sites with a digital camera mounted on the 
microscope (HDcam Hamamatsu 1394 C8484-05G, Hamamatsu, Germany), as 
depicted in Figure 22. No interference between the magnetic and the imaging 






Figure 22: Zeiss Microscope placed few millimeters above the skin-fold chamber that exposes the 
confined part of the dorsal vasculature to a high magnetic field (1039 mT). The configuration 
features fluorescence imaging (right) and enables real time assessment of the retention efficiency 






Magnetic trapping of Microbubbles in the microvasculature of the dorsal skin: 
After injection of the lipid microbubble suspension, the electromagnet was 
activated and supplied with a voltage of 100 V leading to a current intensity of 5 A. 
The magnetic flux density at the tip of the magnet was measured to 1039 mT. 
 
Using  microscopy,  the  vessels  of  the  dorsal  skin  of  the  mouse  were  optically  
inspected for appearance of microemboli or thrombi after magnet activation. The 
observation was made that immediately after magnet field triggering, the blood flow 
started slowing down progressively until it reached cessation in the visible capillaries 
and arterioles of the skin chamber after few minutes. This observation is termed 
Microembolization and certifies the creation of a thrombus due to the 
agglomeration of nanoparticle carrying microbubbles at target site. 
 
The magnetic attraction was so strong and the exposure of the microbubbles in 
the vessels so high that a retention effect was evidenced already in the artery, 
despite blood flow velocities reaching 20 cm/s therein. This retention could be –
reproducibly- generated. 
 
Whereas microbubbles tend to naturally embolize smallest capillaries of 5 to 7 µm 
just due to their size (ranging through aggregation capabilities from 1 to 12 µm), the 
embolization of bigger arterioles of up to 500 µm, as observed in this experiment, 
was only reached by magnetic retention. 
After 4-5 minutes, a further observation was made that the microbubbles started 
gathering in the veins and retention was achieved in both blood vessel types. 
 
Immediately after magnet deactivation, the microbubble agglomeration was slowly 
dissolved and normal blood flow gradually re-established. 
 
It is at this stage noteworthy to recall that the observed thrombi represent no 
threat to the organism of the animal, as they are rapidly dispersed after retention 
stop and due to the significant distance separating them from the heart, lungs and 
brain. 
Figure 23 shows the fluorescence tracking images obtained and the effect observed 









Figure 23: Fluorescence tracking under microscopy of microbubble agglomerations in the arteries 
of a mouse (dorsal skin). From top to bottom, the pictures show the gradual formation of the 






The retention effect can be tuned by changing several parameters of the 
experiment, yet it can be optimized by adjusting the concentration of microbubbles 
used. 
The successful retention leads to the deployment of the therapeutic agent at target 
site, enabling thus the proliferation within 48h of new capillaries in the case of 
angiogenesis supporting biosubstances. Similarly, the therapy can also aim at the 
opposite, namely blocking the formation of new blood supply, by using specific 
oligonucleotides. The inhibition of pathological angiogenesis or the overexpression 
of a defined molecule is one of the main applications of magnetically targeted gene 
delivery. 
When inspecting the genome, mice are considered to be close enough to human 
beings (Chris Gunter, 2002), to enable transposing several results to pre-clinical 
application, especially in the case of new blood vessel creation. This suggests that 
reaching comparable magnetic trapping results of nanoparticles in human 
vasculature is plausible. 
 
As a continuation of these experiments, further tests involving quantitative 
methods and ultrasound destruction of the microbubbles were presented in the 
paper of Mannell et al. (Hanna Mannell, 2012), where gene delivery to specific target 
sites in the vasculature of the mouse has been achieved based on a systemic 
application, enabled through magnetic targeting of nanoparticle coated 
microbubbles that were disrupted by ultrasonic waves. The microbubbles loaded 
with dsRed plasmid DNA were injected intra-arterially and retained at site using the 
magnetic system presented in chapter 3.2. By quantitative real-time PCR, dsRed 
expression was detected only in the targeted area, and when both magnetic field 




Figure 24: Results of site specificity of gene delivery mediated by magnetic microbubbles as 
achieved in the skin-fold chamber vasculature of a mouse (Hanna Mannell, 2012). The expression 






Here, it should be pointed out that the application of ultrasound waves after 
retention  has  to  be  limited  to  a  short  time  in  order  to  prevent  the  over-





4 Magnetically guided nanoparticles for drug targeting 
in the lungs 
Drug Targeting basically involves three major steps: the active guiding and 
steering of carriers loaded with therapeutic substances, the selective overcoming of 
natural barriers within the organism such as the blood-brain-barrier or cellular 
membranes,  and  setting  free  the  active  load  at  target  site,  so  that  a  therapeutic  
effect can be achieved. The targeting can be significantly enhanced through the use 
of magnetic nanoparticles as carriers and the application of adapted magnetic fields 
to control their navigation. This mechanism can be implemented not only in the 
blood vessels, but it is also suitable for other media circulating in the body such as 
the air. 
In fact, targeted delivery of magnetic nanoparticles, accordingly encapsulated in 
aerosols, can be applied to treat diseases in the lungs, which is generally defined as 
the technique of Lung Drug Targeting (LDT). 
Especially for cancer therapy in the lungs, but also for other ailments of the 
respiratory system, LDT presents an important potential, given the fact that the 
internal tissues of the pulmonary pathways are intrinsically more difficult to access 
through blood than through air circulation. 
 
The implementation of this technique involves nebulizing a drug solution and 
mixing it with magnetic nanoparticles to generate aerosol droplets exhibiting 
magnetic properties. These „nanomagnetosols“ can be steered through external 
magnetic fields, and retained and concentrated at target sites (Dames, 2007), which 
would increase the locally delivered active dose compared to classical aerosol 
therapy. This approach is most promising in relation with the application of 
chemotherapeutic drugs to lung carcinomas, where a focused deployment of the 
therapeutic effect automatically leads to the reduction of side effects generally 
observed  in  the  whole  organism  due  to  the  non-selectivity  of  the  used  drug  or  its  
application mechanism. 
 
Gradually, significant advances in the exploration of Lung Drug Targeting have 
been reported.  Since the in-vitro experimentation of  Ally  et  al  in  2005 who used a 
model to study and prove the feasibility of targeted delivery of chemotherapeutic 
substances attached to inhaled aerosols (Javed Ally, 2005), a remarkable progress has 
been achieved by Dames et al in 2007, when the successful pre-clinical application of 
this method was demonstrated in mice lungs (Dames, 2007).   





investigation. Hereby, it is of great utility to take into consideration the fact that a 
diseased lung is usually significantly different from a healthy one. As a matter of fact, 
pathologies in certain areas of the lung inevitably lead to a degeneration of their 
function. Beyond this constraint, the lungs are also subjected to a continuous motion 
due to breathing, which imposes an additional challenge on the treatment 
methodology and the planning of the magnet application (Gläßner, 2008) (Dahmani Ch., 
2008). A further important aspect that needs to be investigated and strongly 
considered in the scope of LDT is the mucociliary clearance of particles deposited in 
the tracheobronchiol region. For instance, studies reported that only 5 % of the 
particles  having  a  diameter  of  6.5  µm  that  are  retained  on  the  inner  walls  of  the  
upper pulmonary pathways escape from mucociliary clearance.  
These are but some of the most pertinent factors that have a significant impact 
on the success of a Lung Drug Targeting procedure. 
In this chapter, an investigation of a number of selected, reportedly crucial aspects 
of this technique will be conducted, based mainly on simulations and experimental 
validation. 
To start, the main requisite for the successful implementation of this therapy is a 
sound understanding of the anatomical constraints related to malignancies of the 
lungs and the upper pulmonary airways. 
 
4.1 Physiology of the human lungs 
The lung is the main respiration organ and is responsible for the transport of 
oxygen from the atmosphere into the bloodstream, and the release of carbon 
dioxide from the bloodstream into the atmosphere. The anatomy of the lungs is best 
understood when the passage of air through the outside to the alveoli is followed 
and described: after progressing through the mouth or nose, air passes in the 
pharynx or throat on its way to the trachea (windpipe). The trachea is divided into 
two main airways upon reaching the lungs, these are the bronchi. One bronchus 
serves the right lung and the other the left. The bronchi further subdivide into 
increasingly smaller branches called bronchioles. Bronchi and bronchioles form the 
so  called  bronchial  tree.  The  divisions  of  this  tree  are  denoted  generations,  and  at  
the level of the 23rd generation, the bronchioles run into alveolar ducts that conduct 
the air to clusters of small air sacs called alveoli (Ozer, 2007). The main constituents of 
the bronchial tree are further illustrated in Figure 25. 
Observed from the outside, human lungs are located in two cavities on either side of 
the heart. The right and the left lungs are not identical and are subdivided by fissures 
into  lobes,  with  three  lobes  on  the  right  and  two  on  the  left  lung.  These  lobes  are  
further divided into segments and then into small, hexagonal compartments called 









Figure 25: Illustration of the main constituents of the human lung comprising the trachea, bronchi, 
bronchial tree and ending up at the alveolar level (National Cancer Institute, 2012) 
 
To understand the challenges related to applying Magnetic Drug Targeting to 
the respiration system, it is of great utility to further observe the involved lung sub-
structures. For instance, a basic treatment scenario would suppose the patient 
inhaling a nebulized solution containing airborne magnetic nanoparticles loaded with 
therapeutic substances and encapsulated into aerosols. These magnetic aerosols, 
also described as nanomagnetosols (Dames, 2007), have to pass the upper airways and 
reach the targeted sites deep in the bronchial tree. Among these upper pulmonary 
pathways, the trachea, main bronchi, and approximately the first dozen divisions of 
smaller bronchi carry rings or patches of cartilage in their walls that prevent them 
from collapsing or blocking the flow of air. The rest of the bronchioles and the alveoli 
do not incorporate a cartilage and are therefore very elastic. This allows them to 
respond to pressure changes as the lungs expand and contract (Kübler, 2007). 
The thoracic muscles enable the deformation of the thorax space, and can 
generate a negative pressure at the lung periphery, which increases the volume in 
the lungs through air inspiration. The expiration is in the contrary achieved through 
the creation of a positive pressure that pushes the air out of the lungs and 
pulmonary pathways. In the case of artificial, mechanical ventilation, these pressure 






Given the fact that the right lung has a bigger volume than the left one, there is a 
tendency to suppose that inhaled airborne substances “prefer” flowing into the right 
lung lobes. 
 
In the case of pulmonary drug delivery, the aspects related to particle 
deposition become of utmost importance. For instance, the size of the inhaled 
particles is decisive for their fate within the pulmonary pathways. This size is defined 
through the aerodynamic diameter which is determined by the actual size of the 
particle, its shape and its density (Ozer, 2007).   For an aerodynamic size between 0.5 
and 3.5 µm, particles bypass the bronchial airways in the inspiration phase and reach 
the deep compartments of the lungs. If the size range is between 3.5 and 6.0 µm, 
particles are able to penetrate -to different extents- beyond the central airways and 
reach the peripheral area of the lung, provided the inspiration is conducted at a low 
flow rate. Particles with a larger aerodynamic size are subjected to their inertial mass 
and therefore tend to impact already in the upper pulmonary pathways, whereas 
smaller particles, with diameters below 0.5 µm, are more exposed to thermal 
interactions with the air molecules surrounding them, which causes them to diffuse 
to the surfaces in the respiratory tract during the inhalation phase (Ozer, 2007). 
 
Foreign particles that touch the inner walls of the respiratory tree get stuck on 
a thin fluid film of mucus covering hair-shaped structures called the cilia. These 
perform a coordinated movement within the mucus layer, that propels up the 
trapped particles to the pharynx and mouth, where they are swallowed (Gläßner, 
2008). This process termed mucociliary clearance is a natural host defense 
mechanism of the airways and has a significant impact on the Lung Drug Targeting 
procedure, as every trapped particle or nano-carrier, including its freight, is 
considered to be lost and does not contribute to the therapeutic effect. 
A good planning and implementation of the LDT technique should therefore involve 
solutions for the mucociliary clearance issue, and reduce, if not avoid undesired 
contact between the airborne particles and the inner walls of the respiratory 
pathways. 
 
Further challenges of Lung Drug Targeting are intrinsically related to the 
parameters of respiration, such as temperature, degree of humidity in the inhaled 
air, the position of the patient and the lungs during treatment, the use of artificial 
ventilation under patient anesthesia, the air flow rate, etc. For instance, the 
introduction of catheters or tubes in the airways during application causes inevitable 
distortions  not  only  in  the  airway  geometry,  but  also  in  the  flow  dynamics  and  
particle behavior. This for example makes it almost unfeasible to correctly assess the 
velocity distribution of air and particles in the pulmonary pathways when 





4.2 Simulating the Lung Drug Targeting procedure 
In the last years, computer simulation has constantly gained in importance as a 
strong and non-invasive tool to study airflow and particle transport and behavior 
during respiration, the main application being aerosol therapy for pharmacological 
purposes. 
To precisely and faithfully reflect in vivo conditions, simulations have to accurately 
reproduce the morphology of the respiratory system, as well as the breathing 
conditions. This implies a physiologically realistic three-dimensional modeling of the 
lungs and the upper airways (Ted B. Martonen, 2001). 
In this chapter, an analysis of the behavior of airborne nanoparticle-loaded aerosols 
in the upper pulmonary pathways is conducted in a simplified lung model. The 
computation of the fluid dynamics and particle trajectories is mainly realized with 
the CFD software ANSYS Fluent (based on the Finite-Volume-Simulation and analysis 
program for numerical fluid mechanics problem solving) in combination with the 
Magnetostatics Module of the FEM based software package COMSOL Multiphysics. 
 
For the simulation of fluid dynamics, numerical methods and algorithms are 
used to describe the motion of fluids, under a number of assumptions. For instance, 
the studied fluid is considered to be a Newtonian fluid, with a constant density and a 
constant viscosity. 
 
This is translated into a set of nonlinear coupled partial differential equations that 
has  to  be  solved.  These  equations  represent  the  laws  of  conservation  of  mass  
(continuity), momentum, and energy, corresponding to the Navier–Stokes equations 
in a modified form (zero viscosity and heat conduction terms) (Issa, 2010). 
 
For the simulation undertaken and presented in this work, the temperature of 
the inhaled air has been assumed constant, so the first law of thermodynamics has 
not been taken into consideration and the solution of the system relied on the set of 
equations (6), (7), (8) and (9) described in chapter 3.1., comprising the Navier-Stokes 
equations and the continuity equation. In an attempt to reduce complexity, 
geometries of tubes have been reported in the literature as adequate models to 
describe respiratory pathways. In these models, the flow of a fluid is said to be 
laminar if the average velocity  is sufficiently small, whereas for higher velocities, 
turbulences and eddies occur, and the flow is said to be turbulent. 
At this stage, it is important to point out a number of relevant quantities that can be 
used to describe the fluid mechanics problem in general: 
 





complete hydrodynamic development and establishment of flow profile.  
- the (dimensionless) Reynolds number Re: is used to characterize different flow 
regimes, such as laminar or turbulent flow. For instance, low Reynolds numbers 
indicate a laminar flow, in which viscous forces are dominant, and the fluid motion is 
smooth and constant, whereas high Reynolds numbers characterize a turbulent flow 
dominated by inertial forces, generating chaotic eddies, vortices and other flow 
instabilities. 
The Reynolds number is given by 
 
= =  ( 34 ) 
where  is the density of the fluid,  its dynamic viscosity,  a characteristic travelled 
length of the fluid, and  the mean velocity of the object relative to the fluid in m/s.  
 
For Reynolds numbers below a critical value Recritical  2300, the motion of the fluid in 
a tube model can be described as laminar. Above this value, the flow is said to be 
instationary (Gläßner, 2008). 
 
For laminar profiles, the following relation can be assumed for Re and  
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[0.0287 ; 0.0575 ] 
 
( 35 ) 
where R is the radius of the observed tube (Gläßner, 2008). 
 
- the (dimensionless) Stokes number: describes the behavior of 
particles suspended in a fluid flow. It is defined as the ratio of the resistance force 
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where  is the aerosol particle density,  is the diameter of the aerosol, R is  the  





The Stokes number is used in the literature to measure to which extent a fluid-borne 
particulate follows the flow. In the case of Lung Drug Targeting, this prediction ability 
is altered due to the impact of the applied magnetic field on the trajectories of the 
nanoparticle-loaded aerosols (Issa, 2010). 
In this work, the magnetic field considerations have been conducted for a 
multiparametric analysis of the particle deposition behavior in the respiratory tract 
under magnetic force application, focusing mainly on the following parameters (Issa, 
2010): 
 
Varied quantity (parameters): Values: 
Flow rate  [l/min] 15, 20, 25, 30 
Aerosol diameter  [µm] 1, 2.5, 3.5, 5, 10 
Magnetic moment of a whole aerosol [Am²] 7.35·10-12, 6.46·10-14, 1.102·10-11 
Angulation of magnetic tip from vertical 
reference [ ° ] 
0, 45, 60, 90 
Activation time of magnetic field [s] 0, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5 
 
Table 6: Parameters varied to study particle deposition under magnetic force application in a lung 
model geometry (Issa, 2010) 
 
Beyond these quantities that have been varied in the scope of the study, a number 
of quantities have been set constant, for instance the air density = 1.109 / ³, 
and the air viscosity = 1.905 / , both independent from temperature. It 
is also assumed that the air inhaled during ventilation is conditioned at entrance to 
reach  a  body  temperature  of  37.5°C.  For  the  used  aerosols,  a  particle  density  of  
= 1005.25  is considered. 
4.2.1 Implemented model geometry for the simulation 
For a realistic asymmetric structure of the human lungs and respiratory 
system, the Model 1 presented by Horsfield et al. has been adopted (K. Horsfield, 1971). 
This model relies on the percental distribution of the outlet air flows, as detailed in 
Table 8.  
 
The simulation being based on the scenario of intubation, the airway model had to 
exclude the extra-thoracic upper airways, i.e. the mouth cavity, the oropharynx and 
the larynx, and to focus on the intra-thoracic central airways of up to 4 generations 
from the zeroth generation (G0) of the trachea to the fourth generation (G4) of the 
airways, with a total of 10 peripheral small airways. Figure 26 depicts the specific 









Figure 26: Denomination of the upper respiratory pathways and main bifurcations, as derived from 
Horsfield’s Model 1 (K. Horsfield, 1971) 
 
 
Airway segments are identified by a nomenclature comprising the letters “l” for left 
and “r” for right side. 
 






angle [ °] 
Curvature radius 
[x radius] 
Trachea 8.00 100.00 100.0000   
L 6.00 50.00 45.0342 73 9.0 
Ll 3.75 16.00 18.9193 48 7.0 
Lr 4.00 11.00 26.1149 44 12.6 
R 5.55 22.00 54.9658 35 6.0 
Rr 3.65 15.60 18.9193 63 3.4 
Rl 4.45 26.00 36.0465 15 4.6 
Rlr 2.60 21.00 9.9316 61 16.0 
Rll 3.20 8.00 26.1149 15 11.8 
 
Table 7: Lung modeling data according to Horsfield’s Model 1 
 
Given these data, the analyzed simulation area was defined as beginning from the 
trachea and reaching the accesses of the five human upper pulmonary ducts. The 
geometry was created using the Physiologically Realistic Bifurcation (PRB) approach, 
in  which  fully  realistic  flow  fields  can  be  computed.  Using  this  geometry,  an  
unstructured polyhedral mesh has been created featuring 651,918 cells in the case 
of non-intubation and 716,000 cells when including the intubation. Figure 27 shows 










Figure 27: Designed geometry (top left) and mesh (top right and bottom) of the upper pulmonary 
airways, based on the Horsfield’s lung data and the physiologically realistic bifurcation 
computation approach (Gläßner, 2008) 
 
In this study, similarly to almost all studies reported in the literature, only the 
impact of a set of factors and parameters could be investigated. An exhaustive 
analysis of all variables is not feasible due to the enormously increasing problem 
complexity. Although the processing capabilities of the newest generations of 
computers  has tremendously  progressed over the last  20 years,  a  compromise still  







Nevertheless, indications derived from the literature are a good basis to identify and 
select the most significant simulation parameters, assumptions and models (Gläßner, 
2008). Common assumptions that are reported in the literature have also been 
implemented into this study and include (Issa, 2010): 
 
- a rigid geometry of the airways 
- smooth inner walls of the respiratory pathways (no tracheal rings) 
- no slip conditions at inner walls 
- laminar air flow (in geometry with no intubation) 
- stationary flow (steady state, no time variation of field quantities) 
- discrete spherical particles as aerosols (with constant mass) 
- unified aerosol diameter 
- particle deposition at wall contact 
-  neglected  forces  acting  on  the  aerosols  stemming  from  Brownian  motion  and  
gravitation 
- neglected interactions between aerosols and with the continuous phase (air) 
 
4.2.2 Magnetic forces and particle trajectories 
The deployment of Magnetic Drug Targeting in the lungs necessitates the 
retention of magnetic aerosols, loaded with therapeutic substances, at target sites 
within the respiratory system. In this workflow, the magnet plays a major role. 
 
The experiments conducted by the research partners in the scope of this project 
involved a strong electromagnet that has been conceived and developed by the 
company Siemens Medical Solutions (Erlangen, Germany) (C. Alexiou, 2006). To 
accompany these experiments on a simulative basis, a 3D modeling of the used 
magnet has been realized using the construction and simulation software COMSOL 
Multiphysics (Version 3.5a). A particularly relevant application of this numerical 
reconstruction was the extraction of magnetic field and field gradient data that were 
used in the computation of the aerosol trajectories and deposition in Fluent. 
 
The Siemens magnet was conceived in a way to guarantee a magnetic field gradient 
with values above 10 T/m in a zone surrounding the magnet tip covering a volume of 












Using the post-processing options of COMSOL Multiphysics, the magnetic flux 
density and the magnetic field gradient were plotted in the relevant space under the 
magnetic tip, as illustrated by Figures 29 and 30. 
 
 








Figure 30: Magnetic field gradient (bottom) in a layer 2 mm under magnet tip. 
 
To further validate the simulation, measurements have been conducted to assess 
the magnetic flux density as well as the magnetic field gradient underneath the 












As the simulation of the Siemens magnet was performed in the three dimensional 
coordinate system, the results of the simulated magnetic field have been compared 
and validated with the measured values in a vertical plane crossing the magnet tip, 
so that a transition between experimental and computed results was assured. The 
results from the simulation are displayed in Figure 32. 
 
To assign a magnetic force to the aerosol particles, the computed values of the 
magnetic field gradient were extracted from COMSOL Multiphysics and transferred 
to Fluent via a so called User Defined Function (UDF). Hereby, the three dimensional 
gradient components were saved as a variable from which the corresponding values 
can be retrieved at each step of the simulation. The magnetic force is then calculated 
according  to  the  formula  (1)  and  used  to  determine  the  acceleration  of  a  given  
aerosol particle following Newton’s second law of motion. 
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Figure 32: Simulated magnetic flux density (top) and simulated magnetic field gradient (bottom) for 
distances given in mm under magnet tip. 






















































































































The magnetic field data extracted from COMSOL are encapsulated in a six column 
matrix with the first three columns dedicated to the coordinates in space of the 
assessed points and the last three filled with the gradient values. Through the 
repartition of the relevant space occupied by the lung model into equidistant layers, 
a mesh containing a defined number of space points was created, with gradient field 
and therefore magnetic force values computed in each single point. A high mesh 
resolution  of  200x200x200  was  adopted  to  guarantee  a  high  accuracy  level  in  





Figure 33: Illustration of extraction layers where the magnetic field data are plotted under the 
magnet tip. 
 
The simulation of the aerosol trajectories was performed using 20,000 aerosols, 
injected following a defined inlet particle distribution calculated for a fully 





each aerosol based on the balance of forces acting on it. The magnet tip was 
positioned  at  the  level  of  the  branch  “lr”  (Figure  24)  in  the  left  lung  to  avoid  the  
intrinsic influence of the higher air flow rate reaching the right lung due to the 
anatomical asymmetry.  
 
The most important results that were achieved can be described in relation to the 
intubation effect and the magnetic field influence. 
On the one hand, simulative evidence was established in case of intubation that (Issa, 
2010): 
 the assumed laminar air flow features turbulences in the region of the 
trachea and the main bifurcation.  
 there was no significant difference in the aerosol deposition rate when using 
different tube ending forms 
 over  50  %  of  aerosols  are  trapped  in  the  main  bifurcation  opposite  to  the  
inlet 
 for aerosols with a 10 µm diameter, the deposition rate increases significantly 
 the magnetic field increases the deposition rate for aerosol diameters up to 5 
µm 
 
On the other hand, the application of a magnetic field gradient led to the following 
observations (Issa, 2010): 
 a positive effect could be registered when varying the activation time of the 
magnetic field. In the inspiration phase, this triggering generated the most 
significant effect when it was synchronized with the aerosol front 
approaching the magnet tip area. For the expiration phase, an optimal 
activation should be considered from t = 0 s. 
 the deposition rate decreases with higher air flow rates, as the airborne 
aerosols rapidly pass through the magnetic trapping zone. 
 the deposition rate decreases for greater aerosol diameters 
 for a successful therapy, higher air flow rates have to be avoided and aerosol 
sizes limited. 








Figure 34 shows the concentration of MNP loaded aerosols subjected to a magnetic 
field gradient positioned over the left lung, with the magnet tip placed orthogonally 






Figure 34: Retention effect on MNP loaded aerosols subjected to a magnetic field gradient 
positioned over the left side of the lung (Issa, 2010). 
 
 
For selected parameters, the diagrams in Figure 35 reveal the influence of the 
variation of the observed quantity on the corresponding deposition rate (in 
percentage of the total number of inhaled aerosols). The main focus of the 
simulative study was accorded to the magnetic field activation time, the magnetic tip 
angle  with  respect  to  the  plane  of  the  target  segment,  as  well  as  the  aerosol  size  








A: Effect of magnetic field activation time on aerosol deposition rate during inspiration (green line for 
total deposition, red line for deposition in the airway segment under magnetic tip) 
 
 
B: Effect of magnetic tip angle above the target segment of  the lungs on aerosol deposition rate 
(green line for total deposition, red line for deposition in the airway segment under magnetic tip)  
 
C: Effect of aerosol diameter and air flow rate on total deposition rate  
Figure 35: Selected results of particle behavior and sedimentation in the proposed lung model 







In conclusion, it can be confirmed that an optimal constellation of parameters exists 
to best plan a Lung Drug Targeting procedure, based on simulative studies. For 
instance,  the main requisites  for  a  maximum aerosol  deposition rate include an air  
flow rate of 15 l/min, a magnet tip placed at an angle of 90° relatively to the vertical 
reference, and a triggering of the magnetic field 0.1 s after aerosol injection into 
tracheal inlet. An immediate consequence of this multiparametric study is the 
possibility to optimize pre-clinical experimentations with a reduced number of 
involved animals. 
 
4.2.3 The effects of intubation 
The multi-parametric study demonstrated that the intubation in the scope of 
Lung Drug Targeting has a tremendous impact on the aerosol deposition rate. This 
can be clearly observed in Figure 36, where a 20-fold higher trapping efficiency is 
achieved when using a tube for inhalation. This effect is furthermore mainly due to 
the positioning of the tube in the trachea, and less to the shape of the tube 
extremity. For instance, a flat or sharp (pointy) tube profile would both lead to the 





Figure 36: Effect of intubation on aerosol deposition rate, with varying aerosol diameter (blue line: 








Beyond the examined cases, deep intubation can be considered, which would lead to 
a more efficient, distal delivery of the aerosols into the lungs. Intuitively, this option 
is completely opposed to the envisaged clinical scenario for LDT application which is 
based on the natural breathing of the patient. On the other hand, a natural 
breathing would inevitably lead to the unwanted deposition of the inhaled aerosols 
in the lower mouth and upper pharynx region. 
4.2.4 Pre-clinical evaluation of Lung Drug Targeting 
In the course of the research program to investigate Magnetic Drug Targeting 
and Lung Drug Targeting conducted by the group of partners 
“Nanomagnetomedizin” and granted by the German Ministry of Education and 
Research, a special attention has been dedicated to pre-clinical experimentation in 
the big animal model. In the scope of this thesis, support has been provided to the 
team around Dr. Carsten Rudolph from the Research Center of the Pediatric Clinic 
and Polyclinic of the „Dr. von Haunersches Kinderspital“ in order to optimize the 
experimentation of MDT on animal lungs. These studies involved the intubation and 
ventilation of experimentation pigs inhaling magnetic aerosols that are retained at a 
given  location  in  the  lungs  by  a  strong  magnetic  field.  The  goal  is  to  increase  the  
concentration of the deposited active agents in the corresponding area 
(Nanomagnetomedizin, 2009). 
 
The aerosols were loaded with the magnetic nanoparticles fluidMAG-D of the 
company Chemicell GmbH (Berlin, Germany) as well as radioactive iodine I125 for 
marking, and directed to the upper respiratory pathways of the animals. The pigs 
were kept under general anesthesia during the treatment. The previously described 
Siemens magnet was used and placed above the targeted thorax compartment 
(Nanomagnetomedizin, 2009). 
 
Figure 37 shows the experimental setup used in these studies and involving the 







   
 
Figure 37: Experimental setup for the preclinical Lung Drug Targeting studies conducted on the big 
animal model (pig) and featuring the positioning of the electromagnet tip. 
 
During experimentation, a cooling system was used to keep the temperature of the 
electromagnet at 25°C. After the application of 10 respiration cycles, the thorax of 
the animal was imaged with a gamma camera then with a CT scanner. Both 
acquisitions were then combined to obtain a full functional cartography of the 
animal. In part of the acquisitions, a PET-CT has been used. 
 
Figure 38 exemplarily depicts the distribution of the radioactively marked 
nanoparticles in the lungs of the treated animal for one single treatment. The bright 
spots in the left lung reveal a significant concentration of aerosols in the 
corresponding regions, particularly at the level of the magnet tip, whereas the rest of 
the lungs is clearly unaltered. 
 
For the described case, the particle concentration and distribution has been assessed 
quantitatively. By way of example, the case documented in Figure 38 features a 
repartition of the detected radioactive particles as follows: 
- Left Lung: 589196 counts, i.e. 63.9% of total number of aerosols deposited 








Figure 38: Distribution of radioactively marked nanoparticles in the lungs of a pig after LDT 
application 
 
The obtained results were in accordance with the outlooks predicted by literature, 
analytical analysis, and simulation. More generally, the animal experiments led to 
the optimization of the ventilation parameters and the properties of the applied 
nanoparticles, which resulted in the successful demonstration of the retention effect 
in the targeted lung region. SPECT-CT images as well as histological investigations 
showed a significant accumulation of magnetic nanoparticles at target site. 
 
In parallel to the evidences achieved through these experimentations on the 
big  animal  model,  it  is  of  great  utility  to  still  consider  the  aspects  that  differ  from  
human application. In fact, differences and variations exist already within the lung 
structures of a given species, let alone when transiting from one species to another. 
Therefore a direct comparison between experimental results in pig lungs and human 
lungs should be avoided, especially in terms of flow conditions and particle 
deposition (Nikivorov A.I., 1985). Moreover, the swine presents a number of 
particularities in its anatomical structures that clearly differ from human physiology. 
For example, the trachea of a pig is relatively longer and more curved when 





first minor branch distally from the main bifurcation, which has an impact on the air 
flow distribution and velocities, as well as the therein suspended particle behavior 
that can not be neglected. These anatomical particularities in the pig can easily lead 
to a higher deposition rate of the applied aerosols at the level of the upper 
pulmonary pathways due to eddies and turbulences. 
A reconstruction of the upper respiratory tract of three different pigs used in the 
experiments is shown in Figure 39 and clearly reveals this anatomical signature. 
 
 
Figure 39: Reconstruction of the upper tracheo-bronchial tree of three different pigs treated in the 
pre-clinical evaluation and exhibiting a first minor bifurcation before the main bronchi 
 
Beyond these pertinent observations, the modeling of the different geometries of 
the involved anatomies for simulative studies also allowed a deeper understanding 
of the ventilation conditions. As a matter of fact, the positioning of the tube in the 
upper region of the trachea could be visualized (Figure 40) under real treatment 
conditions and revealed a tendency to direct the inhaled airflow towards the inner 
walls of the windpipe, causing -in a number of treated animals- an unusually 




Figure 40: Reconstruction of the upper bronchial tree of an experimentation pig including the tube 
used for ventilation. The inclination of the tube explains the unusually increased aerosol 






4.3 Breath-synchronous lung drug targeting 
Lung  Drug  Targeting  is  certainly  one  of  the  most  promising  methods  to  
efficiently treat diseases of the respiratory system, such as carcinomas in the lungs. 
However, first implementations of this technique, as described in the pre-clinical 
studies presented in chapter 4.2.4 still present room for improvement. One of the 
suboptimal aspects of the current treatment scenario is the facto f assuming a 
continuous application of the magnetic field all through the inspiration and 
expiration phases of the artificial respiratory act that supplies the patient.  
During experimental investigations, it was observed that applying the field this way 
forced the magnetic aerosols to sediment at regions far from the target site, mainly 
in the trachea and main bronchi, because of the force inducing magnetic field 
gradients that are present over the whole field application area. 
 
Considering these effects led to the development of an optimized approach 
consisting in: 
- punctually generating the aerosol cloud exactly at the beginning of the inspiration 
phase, which would propel the particles to the deepest parts of the lungs and 
therefore to the targeted cells as well 
- synchronizing the magnetic field activation with the breathing process, so as to 
trigger the magnetic trapping right when the aerosols have reached the target site 
 
Further elaboration on this approach involves analyzing the relevant 
respiration parameters such as pressure and flow in order to detect the end of the 
inspiration phase and trigger the magnet exactly at the point in time, when particles 
have reached the deepest alveoli at target site, and are no more subjected to forces 
due to the streaming. The magnetic field is then held on during the expiration phase 
to assure the retention of the aerosols at the targeted sites, which increases the 
efficiency and focality of the treatment. This way, only target cells are subjected to 
the deposition of the drug carrying aerosols, while the other healthy regions of the 
lungs remain unaltered by side effects (Dahmani Ch., 2008). 
 
This inevitable improvement of the concept of Lung Drug Targeting through the 









Figure 41: Time schedule for magnetic field activation in an optimized, breath-synchronous Lung 














5 Cellular uptake of nanoparticles following successful 
targeting 
The ultimate goal of Magnetic Drug Targeting is to selectively bring a substance 
capable of deploying therapeutic activity to an ailment site in the body, using natural 
circulation pathways, such as blood vessels or respiratory pathways. Yet, successful 
therapy is only achieved, when the therapeutic load carried by the guided 
nanoparticles is internalized into the target cells and triggers a healing process, 
either through necrosis -when the intended effect is eliminating the cell-, or through 
the initiation of a therapeutic protein production activity within cells, in the case of 
gene therapy. 
In both variations, cellular uptake of the internalized bioactive substances and/or 
genetic material is indispensable. 
 
Several techniques have been developed to overcome cell membranes and 
enhance substance delivery into cells. This process is called cell transfection, or 
transduction, when it involves the use of viruses or viral shells as mediators or 
carriers for the transported load. Usually, these two approaches are referred to as 
viral and non-viral gene delivery. In fact, viruses are very efficient in delivering genes 
into cells, but they lack safety. This motivated researchers to explore alternative 
ways of overcoming cellular barriers that –even if not as efficient as viruses- hold the 
promise of safety and reproducibility. Among other advances, self-assembled 
nanosystems have been investigated for targeting subcellular organelles (Torchilin, 
2006). 
 
Applying controlled and enhanced transfection methods presents several 
advantages, including faster operation and higher rates, and has become routine in 
daily biological work, making it for instance possible or considerably easier to 
produce proteins for clinical or research applications, to add genetic markers to cell 
lines and more generally to study DNA replication, recombination and mutation. 
 
In this section of the study, ways of applying improved transfection techniques to 
assure the cellular uptake of the delivered bioactive substance at the magnetically 










5.1 Enhancing cell permeability with static magnetic fields: 
MagnetofectionTM 
Transfection, defined as the non-viral process of introducing substances into 
cells, plays a significant role in molecular biology and genetic engineering. It enables 
the mass manufacturing of pharmacological or biological beneficial products, and 
leads to an industrial exploitation of genetically modified cells or bacteria (C. 
Bergemann, 1999). 
Transfection is also indispensable in magnetic drug targeting and gene therapy 
where nucleic acids (genetic material) constitute the transported load, comprising 
plasmid DNA or siRNA fragments, or proteins, e.g. antibodies, and have to be 
selectively conducted to the subcellular compartments. 
When the cargo comprising the genetic material is delivered into the cell, the 
proteins encoded therein are expressed, i.e. replicated by the cell and amplified, 
deploying thus a therapeutic effect.    
Especially in drug delivery, the challenge goes beyond ensuring the uptake of these 
substances into the cells, as the real target sites are mostly in the intracellular space 
(cytoplasm) or even in the nucleus. 
To make molecules traverse the cell membrane, many techniques have been 
explored and applied. For instance, electroporation, involving exposure to high 
voltage electric fields, sonoporation, based on the application of ultrasound waves, 
or particle bombardment have been reported to mediate cell transfection (Chao-Bin 
Chen, 2009). 
The generality that can be observed from these different approaches is the 
necessity  to  create  transient  openings  or  pores  in  the  cell  membrane,  allowing  for  
material transport and uptake. This process should be in analogy with the natural 
cellular uptake mechanisms for nanoparticles and macromolecules, involving 
pinocytosis, endocytosis, and receptor-mediated endocytosis (Challa S.S.R. Kumar, 2005). 
Figure 42 illustrates these different techniques. 
 
Living cells possess plasma membranes that are characterized by a dynamic, 
lipophilic structure. It follows from this that the entry of large, hydrophilic, or 
charged molecules into intracellular space is limited. Because most genetic 
molecules are not only charged but also relatively large in size, they cannot cross the 
cell  membrane  on  their  own,  but  have  to  be  delivered  to  the  cytoplasm  using  an  








Figure 42: Natural mechanisms of cellular drug uptake into tumor tissue, as illustrated in (Challa 
S.S.R. Kumar, 2005) 
 
A particularly successful development responding to this challenge has been 
the assembling of synthetic or non-viral gene delivery systems. Especially the latter 
present pertinent advantages, such as their ease of use and simplicity of production 
in important quantities. Non-viral methods also prevent the triggering of nonspecific 
inflammations followed by unintended immune responses (Ikramy A. Khalil, 2006). 
 
In addition to the increasing tendency of using non-viral gene delivery systems to 
perform the biotechnological maneuver of transfection, the use of nanoparticles 
combined with magnetic fields has also gained in importance over the last years. 
  
In fact, researchers exploit magnetized nanoparticles not only for the guidance 
and control of substances within blood vessels and respiratory pathways, or for 
cellular and macromolecular separation processes (Wei, Lee, & Lai, 2009) (José Luis 
Corchero, 2007), but also to reproducibly enhance the rate of cell transfection. 
It  is  here  of  great  utility  to  underline,  that  the  process  of  cellular  uptake  is  mainly  
limited by the insufficient contact between traditional delivery systems and target 
cells (Tristan Montier, 2008), leading to sub-optimal transfection rates. 
 
By adequately coating and loading magnetically activated nanoparticles with DNA 





the inner parts of cells (C. Bergemann, 1999),  Plank  et  al.  were  among  the  first  
researchers to report successful implementations of this magnetically mediated 
transfection and established this method in 2000 as the technique of 
Magnetofection™ (Plank C., 2000). 
 





Figure 43: Illustration of the Magnetofection technique, consisting in the nucleic acid delivery to 
target cells guided and enhanced by the action of magnetic gradient fields on gene vectors 
associated with magnetic particles. 
 
The main strength of this technique is the enhanced contact of transported 
vectors with target cells, as the used magnetic nanoparticles associated with nucleic 
acids are prevented from diffusion and forced to sediment onto the surface of cells 
within short times (Vainauska D, 2012). 
In accordance with this explanation, Magnetofection has shown tremendous 
improvements in transfection efficiency of reporter genes, as compared to 
conventional transfection methods (Plank C, 2003). These improvements have been 
reported in vitro and in vivo (F. Scherer, 2002), and for different gene types and cell 
lines, including neuronal and glial cells, tumor and embryonic cells, as well as 
endothelial and epithelial cells (José I. Schwerdt, 2012). 
 
One further major advantage of the magnetically actuated transfection is the 
intrinsic ability to use the magnetic field to separate the transfected cells -containing 
for instance magnetic nanoparticles- from the non-transfected cells, avoiding, so, 





5.2 Cell transfection with dynamic magnetic fields 
The achievements realized through the investigation of magnetofection 
represent an enormous potential for this technique to complete the technology of 
Magnetic Drug Targeting. The combination of both methods is intuitive, as in each of 
them, magnetic fields are used to exert attraction forces on nanoparticles carrying 
therapeutic loads. 
Provided the external magnetic fields are properly activated and concentrated to 
retain the nanocarriers, they can also be accordingly focused to enhance cellular 
uptake of the transported bioactive agents. Consistent with these outlooks, it can be 
imagined that the therapeutic load carried by the nanoparticles comprises genes 
coding for a certain therapeutic molecule. Once this genetic material is delivered to 
the intracellular milieu, the target cells start producing their “medicine” by 
themselves. Such a promising scenario highly depends on the efficiency of the 
transfection  method  used.  Therefore,  it  is  of  great  interest  to  investigate  ways  of  
improving cellular uptake mechanisms for magnetically targeted substances.  
In this chapter, approaches to enhance the efficiency of magnet assisted transfection 
are explored. These are based on the extension of the classical static magnetic fields 
-proven  to  accelerate  vector  deposition  at  the  cell  surface-  to  dynamic  magnetic  
gradient fields. 
 
In fact, time-varied magnetic fields have been reported in an exploratory phase 
to facilitate the transport of magnetic nanoparticles in artificial cytoplasm-like 
media, such as viscous gels (Hanjie Wang, 2010), and recently, alternating or pulsating 
fields were reported to definitely increase magnetofection efficiency (Sarah W. Kamau, 
2006). For instance, Kamau et al. used a Dynamic-Marker magnetic device to 
generate a sinusoidal wave exhibiting a peak amplitude of 27 mT and a field gradient 
of 10 T/m perpendicular to a cell culture exposed on a well plate. The frequency of 
this component of the alternating field was 50 Hz. Additionally the “magnetic waves” 
had parallel components to the plate’s surface that oscillated at 0.75 Hz. Kamau et. 
al reached an average increase of up to a 2-fold in the transfection rates compared 
with an exposure to a static magnetic field, and further reported improved 
transfection in the case of primary cells, including synoviocytes, chondrocytes, 
osteoblasts, melanocytes, macrophages, lung and embryonic fibroblasts (Sarah W. 
Kamau Chapman, 2008). Based on the same principle but using a different setup, Chen 
et al. exposed mammalian cells and Escherichia coli (adherent and in suspension) to 
pulsed magnetic fields of millisecond duration and featuring amplitudes of 0.6 T, and 
achieved in defined cases a more rapid transfection. Given the strong dependency of 
the transfection efficiency on the used magnetic particles, the number of magnetic 





reached through pulsing three times with magnetic fields of up to 2.15 T (Chao-Bin 
Chen, 2009) (Ji-Yao Chen, 2006). 
A particularly convenient implementation of the same concept was realized by Jon 
Dobson’s team who developed and commercialized a system generating alternating 
fields based on a conventional magnetic plate array moved below a cell culture 
support at a low frequency and small amplitude. Improvements in the transfection 
efficiency of cell lines and primary cells could be achieved using this setup (Pickard M, 
2010) (Fouriki A, 2012) (McBain SC, 2008). 
  
In  the  frame  of  this  thesis,  a  magnetic  system  following  the  same  principle  of  
pulsating magnetic fields, yet exploiting a different concept, has been developed. 
5.2.1 Rotational magnetic system and pulsating fields for cell 
transfection 
As reported in the literature, most of the systems used to generate magnetic 
pulses for biological applications are based on electromagnets. Yet this concept 
presents major drawbacks with regards to highly sensitive cell experiments. For 
instance, Eddy currents and the resulting heating in electromagnets generate a 
variation in the electric current flowing through their windings (Eberhard Kallenbach, 
2003) (C. Alexiou, 2006), which not only leads to instabilities in the developed magnetic 
field and the overall experimental parameters but also represents a danger and a 
disturbing factor for the treated cells. 
 
To exclude the drawbacks of electromagnets in the process of enhancing cell 
transfection with magnetic pulses, a new concept needed to be elaborated, that 
would only involve permanent magnets and still generate the necessary variable 
field. To be able to deliver pulsing fields with these magnets, a comparable 
mechanical system that assures a very rapid transient change in the magnetic flux 
density surrounding the nanoparticles has been conceived. 
An eventually translational movement of a permanent magnet would not be as fast 
as needed and therefore could not deliver the needed changes in terms of field 
strength. Therefore, the approach capable of generating the intended pulses 
involved a rotating system which keeps the flux density in the targeted region 
varying rapidly over the time. The estimated pulse magnitude should hereby exceed 
6*10-3 to 7*10-2 T and the pulse duration should ideally be in the range of 10-5s to 
10-1s (Timothy E. Vaughan, 1996). 
 
The concept was implemented in simulations to predict the behaviour of the flux 







Figure 44: Magnetic flux density distribution (in T) and magnetic field lines of the simulated magnet  







Figure 45: Magnetic flux density distribution (in T) and magnetic field lines of the simulated magnet 






The conceived system was therefore modelled in COMSOL Multiphysics and 
consisted of two permanent magnet rods (10x20x120 mm) rotating counter-
clockwise and separated by a distance of 20 mm. Each of them had a remanent flux 
density of 1.43T. 
 
The two magnet rods were placed following 4 possible arrangements, as depicted in 
Figures 44 and 45, with a magnetization along the width and along the depth of the 
rod, in parallel and anti-parallel direction. 
 
The rotation was modeled using a deformed mesh application mode, in which the 
center part of the geometry, containing the rotating magnets and the space between 
and surrounding them (indicated through the index "rot"), rotates with a rotation 
transformation relative to the default coordinate system (indicated through the 
index "stat"). The rotation of the deformed mesh is defined by the transformation 
 
= cos( sin( )sin( ) ( )  
 
where  is the angular frequency. 
 
The rotating magnetization was also implemented following the same 
transformation (Comsol Multiphysics, 2009). 
 
The results of the simulation were then adjusted according to the constructed 
system involving two permanent magnet cuboids made out of Neodymium-Iron-
Boron (NdFeB) with a 10 micron coating of Nickel (Ni+Cu+Ni) and having a residual 
induction of Br =  1.43T.  The  magnet  was  controlled  with  a  brushless  motor  system  
that rotated up to 4000 turns per minute, which corresponds to a maximum 
frequency  of  2  x  4000/60  s  =  133.33  Hz;  a  sample  treated  with  this  magnet  
constellation would experience two pulses with every revolution of the magnet pair. 
 
As shown in Figure 46, a well holder was constructed to suit the used “Nunc 
BreakApart” detachable wells and was positioned along the axial axis of the 
magnetic  system.  Two  variant  well  holder  platforms  were  used,  allowing  for  two  
placement possibilities for the wells, with distances r from the system centre equal 
to 4 and 7.5 mm, corresponding to magnetic flux densities of B1 = 190 mT and B2 = 












Figure 46: Top: the constructed rotating magnetic system with brushless motor, bottom: well 
holding disc (right) and multilevel well holder (left) for magnetic exposure of cells 
 
The developed rotational magnetic system produced the expected sinusoidal 
pulse forms at the chosen reference points. The diagrams in Figure 47 show the 
simulated magnetic flux density [in T] and the field gradient [in T/m] at a distance of 
7.5 mm from the system centerline, featuring an amplitude of 310 mT and a 
frequency of 10 Hz. As the direct measurement of these values over the time in the 
space between the cuboids was not possible during system rotation, the simulation 







Figure 47: Magnetic flux density and magnetic field gradient at a distance r = 7.5 mm from the 
system center and a frequency f = 10 Hz 
5.2.2 Experiments 
With the developed magnetic system, cell transfection experiments were 
conducted on adherent as well as suspension cells, using magnetic 
nanoparticle/plasmid complexes. 
 
The used magnetic nanoparticles: 
For the transfection experiments, two kinds of nanoparticles have been used. For the 
trials involving adherent cells, the PEI-Mag2 magnetic nanoparticles, as described in 
Chapter 2.1 were used, whereas for the suspension cells, SOMag5 core/shell-type 
magnetic nanoparticles were applied. These had an iron oxide core with an average 
crystallite size of 6.8 nm and a silica oxide coating with surface phosphonate groups; 
the surface phosphonate groups were formed by the co-condensation of tetraethyl 
orthosilicate and 3-(trihydroxysilyl)propyl methylphosphonate. The mean 
hydrodynamic diameter and zeta potential of the MNPs suspended in water were 





magnetisation per unit of iron weight at 298 K was 94 emu/g iron. The aqueous MNP 
suspensions were sterilised using 60Co gamma-irradiation (25 kGy).  
 
The cell culture: 
For the experiments in adherent cells, NCI-H441 human pulmonary epithelial cells 
were cultured. Referred to as H441 cells, they were derived from a papillary 
carcinoma of the lungs (ATCC, cat. no. HTB-174). The used culture medium 
comprised  modified  RPMI  1640  medium  with  2  mM  L-glutamine,  10  mM  HEPES,  1  
mM sodium pyruvate, 4.5 gl-1 glucose, and 1.5 gl-1 sodium bicarbonate supplemented 
with 10% heat-inactivated FCS, 100 U/ml penicillin, and 100 g/ml streptomycin. The 
cells were grown at 37°C in a humidified atmosphere containing 5% CO2. 
For  the experiments with suspended cells,  Jurkat  T  cells  were obtained from DSMZ 
(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, cat no. ACC 
282)  and  maintained  at  37°C  and  5%  CO2 in RPMI 1640 medium (Gibco-BRL, 
Eggenstein, Germany) supplemented with 10% foetal calf serum (FCS), 2 mM D-
glutamine, 100 U/ml penicillin and 100 g/ml streptomycin (complete medium) at a 
density of 0.75 to 1.5 million cells/ml. Every 2–3 days, at a density of approximately 
1.5 million cells/ml, the cells were split 1:2. The cells were used for transfection 
experiments until 13–15 passages after thawing. 
 
Preparation of the magnetic lipoplexes: 
The luciferase reporter plasmid p55pCMV-IVS-luc+, which contains the firefly 
luciferase cDNA under the control of the cytomegalovirus (CMV) promoter (pLuc), 
was amplified and purified. The GFP reporter plasmid containing the enhanced green 
fluorescence protein (peGFP) sequence under the control of the CMV promoter was 
expanded in E. coli and purified using the Qiagen plasmid purification kit. 
Magnetic lipoplexes were prepared with eGFP or luciferase plasmid DNA and the 
DreamFect™ Gold (DF-Gold) as an enhancer at a MNPs/DF-Gold/pDNA ratio of 
0.5:4:1 (iron w/v/w). For magnetofection of the adherent cells, PEI-Mag2 
nanoparticles  (5  µg  Fe  in  20  µl  of  water)  were  mixed  with  40  l  of  the  DF-Gold,  
followed by the addition of 40 l (10 µg) of the pLuc solution in a serum- and 
supplement-free RPMI 1640 medium. The suspension was kept at room temperature 
for  20  min  to  allow  complex  assembly.  Then,  the  volume  was  adjusted  to  2500  µl  
with supplement-free RPMI 1640 medium, and 25 µl of the complex solution was 
added to the 25000 cells in a well, resulting in a dose of 4 pg plasmid per cell.  
For the magnetofection experiments involving the suspension of Jurkat T cells, the 
SO-Mag5 MNP suspension (25 µg Fe) was mixed with 150 µl of DF-Gold, followed by 
the  addition  of  5  l  (25  µg)  of  the  peGFP  solution  and  5  l  (25  µg)  of  the  pLuc  
solution  in  serum-  and  supplement-free  RPMI  1640  medium  for  a  total  volume  of  
500 µl. The DF-Gold/pDNA lipoplexes were prepared using water instead of the MNP 





plasmid per cell. The use of mixed complexes containing both the pLuc and peGFP 
plasmids  allowed  for  the  analysis  of  the  protein  expression  and  the  percentage  of  
transfected cells with the same probe. 
 
Transfection of adherent epithelial cells with magnetic lipoplexes using different 
exposure patterns: 
The developed rotational magnetic system was designed for the treatment of cell 
populations confined in detachable wells. Therefore, H441 cells were trypsinised and 
seeded in the Nunc BreakApart lose wells, as depicted in Figure 48, and resuspended 
in  the  cell  culture  medium  at  a  density  of  1.67x105 cells/ml. 150 l aliquots of the 
obtained cell suspension were then transferred to the detachable wells of a 96-well 
plate, resulting in 25,000 cells per well and a confluence of approximately 40%. After 
incubating the cells for 24 h, 25 l of one of the prepared magnetic transfection 
complexes, which contained 100 ng of plasmid, was added to each well. The plates 
were then exposed to a magnetic field for 15 minutes. For this, a magnetic plate (see 
Figure 48) was placed under the BreakApart plate with the detachable wells to 
induce sedimentation of the magnetic transfection complexes at the cell membrane, 





Figure 48: Top: magnetic plate used in classical magnetofection, bottom: the used detachable wells 






The transfection experiments were conducted with respect to three patterns of 
exposure to the magnetic field. All wells were closed with grip stoppers and exposed 
to the static magnetic field of the magnetic plate for 15 minutes (reference group). 
The duration of the exposure to the magnetic field pulses was 30 seconds for all of 
the samples in the experimental groups. 
In the first pattern, the cells were exposed to a pulsating magnetic field directly after 
exposure  to  the  static  magnetic  field,  i.e.,  at  time  t  =  0  s.  The  second  treatment  
pattern included 30 s  of  exposure to the magnetic  field pulses at  t  =  0 s  and again 
one hour after exposure to the magnetic plate (at t = 1 h). In the third pattern, the 
cells were treated with pulses only one hour after exposure to the static magnetic 
field. 
The patterns of the magnetic field pulses: 
- Group 1: only at t = 0 s 
- Group 2: double exposure, at t = 0 s and t = 1 h 
- Group 3: only at t = 1 h 
- Group 4: reference group (only static magnetic field applied) 
 
Five  magnetic  field  frequencies  (2.66,  5,  10,  50,  and  100  Hz)  and  two  average  
magnetic  field  amplitudes  at  the  location  of  the  cells  (190  and  310  mT)  were  
assessed. 
After exposure to the static and pulsed magnetic fields, all of the samples were 
incubated at 37°C in a humidified atmosphere containing 5% CO2 until the reporter 
gene analysis was performed. Each group included triplicate samples. 
The expression of luciferase was assayed by measuring the chemiluminescence 
intensity of the luciferin-luciferase light-producing reactions in the cell lysate 
(Mykhaylyk O. A., 2007). The significance of the difference between the data sets was 
analysed using Student’s t-test. 
 
Transfection of suspension Jurkat T cells: 
To explore the effect of pulsating magnetic fields on transfection efficiency, it was 
important to consider not only adherent cells, but also cells in suspension. For this, 
Jurkat T cells were labelled with anti-CD2 MicroBeads and treated by 
magselectofection which is defined as the combined isolation and stable nonviral 
transfection of cells using magnetic fields. 400 µl of magnetic lipoplexes were 
allowed to seep into the Miltenyi LS cell separation column, which was subsequently 
positioned in a MidiMACS Separator magnet to immobilise the homogeneously 
distributed magnetic vectors. The magnetically labelled cells (2 million) were applied 
to a vector-modified column, and the column was then positioned in the MidiMACS 
magnet, where it remained for 30 minutes at room temperature. Subsequently, the 





ml test tubes by pressure-enforced elution. Additionally, non-labelled cells were 
transfected with DF-Gold/pDNA complexes (lipofection), and CD2-Microbead-
labelled Jurkat T cells were associated with the magnetic triplexes; both processes 
occurred at a cell density of 1 million per millilitre without the application of the 
static magnetic field. For the treatment with rotational magnetic field pulses, 150 l 
aliquots of the cell suspension were transferred to the detachable wells and placed 
into the holder. The alternating magnetic field was then applied for a duration of 120 
s,  and  at  the  following  pulse  frequencies:  2.66,  5,  10,  20  and  50  Hz.  The  average  
magnetic  field  amplitude  was  190  mT  at  the  location  of  the  cells.  Reporter  gene  
expression analysis was conducted 48 hours after magselectofection using 
fluorescence-activated cell sorting (FACS) analysis (based on eGFP) or a luciferase 




Enhanced transfection of adherent cells induced by magnetic pulses: 
In accordance with the three above mentioned treatment patterns, the adherent 
H441  cells  were  transfected  and  treated  with  pulsed  magnetic  fields,  after  which  
they were analysed based on the luciferase reporter expression. The pulsatile 
transfection approach with pulse amplitudes of 190 mT and 310 mT generated, in 
almost all samples, a higher luciferase expression than that of the reference group of 
samples, which were treated only with the static magnetic field.  
 
 

























Luciferase Expression of cells exposed to B1 pulses 
(190mT)








Especially the treatment according to the first pattern at lower frequencies, from 
2.66 to 10 Hz, led to higher transfection rates than those in the reference samples, 
whereas the two other pulse field patterns delivered more moderate enhancements 
in the transfection efficiency. 
 
As can be further seen in Figures 49 and 50, increases in reporter gene expression of 
36%  and  52%  at  frequencies  of  2.66  Hz  and  10  Hz,  respectively,  (t=0  treatment  
pattern) relative to the reference data (only static magnetic field application) were 
observed, and fulfilled the quality of statistical significance (p=0.02 and p=0.004, 
respectively). A slightly negative effect on the transfection rate was observed for the 
higher frequencies of 50 and 100 Hz when the cells were exposed to the pulsating 
field immediately after the basic treatment, leading to a decrease in the transfection 
efficiency. 
 
An increase in the transfection rates, yet to different extents, was reached by the 
stronger magnetic pulses of 310 mT. It is worthy to note that the lower frequencies 
persisted in being the frequencies showing the higher effects. The relative increase 
of  27%  for  f  =  2.66  Hz  after  double  exposure  at  t  =  0  and  t  =  1  h  and  the  
augmentation  of  23%  for  f  =  10  Hz  after  single  exposure  at  t=1  h  relative  to  the  
transfection rate of the reference were statistically significant (p=0.015 and p=0.022, 
respectively). The exposure pattern that was limited to a single treatment after one 
hour  with  magnetic  pulses  of  both  190  mT  and  310  mT  resulted  in  a  moderate  
increase for almost every implemented frequency (Ch. Dahmani, 2012). 
   
 
 
Figure 50: Luciferase expression in adherent H441 human lung epithelial cells after magnetofection 
and 30s exposure to pulsatile magnetic fields following the three treatment patterns (Ch. Dahmani, 
2012) 
 






Evaluation of cell viability: 
 
To assess the cell viability after the exposure and treatment with magnetic fields, the 
magnetically transfected cells were washed with PBS after 72 h of incubation with 
the complexes. An MTT-based assay was used and the cells were further incubated 
for 2 h in 100 l of 1 mg/ml MTT  prepared  in  PBS  with  5  mg/ml glucose in a well 
plate. Afterwards, 100 l of a solubilisation solution containing 10% Triton X-100 in 
anhydrous isopropanol containing 0.1 N HCl was added to each well to dissolve the 
formazan. The optical density was measured at 590 nm, and the cell viability was 
expressed as the respiration activity normalised to the reference data for the 
untreated cells. Cytotoxicity was determined by measuring the total protein content 
with BioRad assay (Ch. Dahmani, 2012). The results in terms of percent of viable cells 




Figure 51: Percentage of viable adherent H441 cells versus duration of exposure to magnetic fields 
pulses (Ch. Dahmani, 2012) 
 
The results obtained clearly proved that the percentage of viable adherent cells after 
pulse application remained above 75 % for the three exposure patterns, whereas the 







Furthermore, no statistically significant differences could be observed between the 
effects  of  the  pulsed  magnetic  fields  with  amplitudes  of  190  mT  and  310  mT.  The  
greatest improvement in the transfection efficiency of adherent H441 cells was 
observed for the lowest frequency of 2.66 Hz for all pulsed MF treatment patterns. 
Table 9 shows the mean change in transfection efficiency (% of reference) when 
using pulsating magnetic fields for all five used frequencies. 
 
 
Frequency (in Hz) 190 mT 310 mT 
2.66 34.9 % 32.8 % 
5 24.1 % 13.6 % 
10 31.2 % 8.4 % 
50 2.2 % 13.5 % 
100 2.8 % 14.5 % 
 
Table 8: Mean change in transfection efficiency expressed in percentage over reference (no 
magnetic field use), for the amplitudes 190 and 310 mT. The data are obtained as averages from the 
patterns t = 0 and t = 0 + t = 1h. 
 
 
Jurkat T cells in suspension 
 
Major results involving suspension Jurkat T cells were obtained through the 
application of alternating magnetic field pulses for a duration of 120s and at a 
frequency of 10 Hz. For instance, a 1.7-fold increase in transgene expression after 
spontaneous association of the magnetically labelled cells with the magnetic vectors 
was observed. Similarly, a 1.9-fold transgene expression increase after 
magselectofection of the magnetically labelled cells could be documented as 
displayed in Figure 52.  
 
The most significant effect generated by the pulsating magnetic field was recorded 
at 5 and 10 Hz, and cell viability levels remained over 100 % for all tested frequencies 
(2.66,  5,  10,  50  and  100  Hz).  In  Figure  52,  statistical  significance  is  rated  with  a  
double  star  **  for  p  <  0.01  and  a  single  star  *  for  p  <  0.05,  and  samples  without  







Figure 52: Left - Effect of the pulsating magnetic fields on luciferase expression and cell viability in 
Jurkat T-cells 48 h after transfection (pulse amplitude B1=190 mT) compared to status with no 
magnetic field, Right - reporter expression and cell viability as a function of the frequency of the 
applied alternating magnetic field after magselectofection of the cells with the complexes bearing 
eGFP coding plasmids (Ch. Dahmani, 2012) 
 
 
Impact of the alternating magnetic field on the transfection mechanism: 
 
After the observations made and covering adherent as well as suspension cells, 
evidence was gained that the increase in transfection efficiency was induced by the 
exposure to magnetic pulses. This resulted more specifically from the magnetic 
responsiveness of the magnetic DNA lipoplexes. 
In comparison with classical static magnetic fields, the rotating magnetic cuboids 
used  in  the  elaborated  system  generate  defined  pulses  at  the  sites  of  the  wells  
containing the magnetic vectors and the adherent as well as suspension cells, which 
exerts strong horizontal drag forces on the magnetic complexes. 
 
Microscopy images, as shown in Figure 53, reveal the spatial distribution of the 
magnetic complexes after standard magnetofection as compared to their 
arrangement after the additional exposure to pulsed magnetic fields that generated 






Figure 53: Comparative microscopic images of the H441 cells between (top) standard 
magnetofection (treatment by addition of the magnetic vectors and incubation for 20 min in the 
presence of the magnetic plate) and (bottom) “dynamic magnetofection” (30 s of treatment with a 






In fact, standard magnetofection implies that the MNP-containing complexes 
are attracted to the magnetic plate placed under the wells and therefore forced to 
sediment on the cell surface. Yet, a significant portion of the complexes ends up 
deposited at the bottom of the plate in the space between the cells and does not 
actively contribute to the cell internalisation and transfection process, thus 
considered to be “lost”. In contrast, MNP/DNA-complexes exposed to the horizontal 
forces generated by the rotating magnets move laterally in the suspension and have 
an increased probability of coming into contact with a cell, being bound to the 
cytomembrane and being internalised into the intracellular space. 
 
The main effect of the magnetic forces on the complexes deposited on the bottom of 
the well is primarily the displacement caused by the magnetic attraction, which can 




where  describes the forces acting on the MNP/load-complexes, such as the 
magnetic force, hydrodynamic resistance, gravity and friction (Timothy E. Vaughan, 
1996).  The  magnetic  force  is  the  major  driving  force  in  this  consideration  and  
increases with increases in the magnetic moment and gradient of the field. The latter 
reaches values of more than 50 T/m in the vicinity of the cells, as shown in Figure 47. 
A  movement  of  the  MNP-DNA  complexes  in  the  culture  medium  parallel  to  the  
bottom of the well can be actuated by the field gradients and increases the 
probability for a complex to collide with a cell membrane. As schematically 
illustrated in Figure 54, the direction of the applied magnetic force plays a major role 
in facilitating the movement of dragged complexes. 
 
Beyond single magnetic nanoparticles, also entire cells loaded with magnetic 
complexes on their surfaces or encapsulated in their intracellular space similarly 
experience magnetic forces and can be dragged and moved in the suspension. This 
movement of the cells facilitates the formation of cell "islands" and agglomerations, 








Figure 54: Schematics of the rotating magnetic forces acting on the magnetic vectors/nanoparticles 




In  the  literature,  it  was  proposed  by  Fouriki  et  al.  that  a  mechanism  of  
oscillating nanomagnetic transfection can be generated through the mechanical 
stimulation of endocytosis when “an oscillating magnet array below the 
surface…pulls the particle into contact with the cell membrane and drags the 
particles from side-to-side across the cells” (A. Fouriki, 2010). Fully aligned with this 
explanation, it has been indeed reported, that mechanical stimuli can have effects 
on cellular membrane trafficking processes, including endo- and exocytosis (Apodaca, 
2002).  
 
Beyond the capacity of pulsed magnetic fields to drag the magnetic vectors to the 
cells, they also enable the creation of transient cell membrane openings. These so-
called pores are created either by direct impact on the membrane or by the 





attraction and repulsion action on the nanoparticles (Timothy E. Vaughan, 1996), driven 
by the applied magnetic forces. 
When considering an energetic approach, it can be demonstrated that during 
sufficiently long magnetic field pulses (10-5 s  <  tpulse <  10-1 s), very little energy is 
dissipated, and the rotational energy from the membrane-associated magnetic 
particles could be deposited temporarily into the membrane as elastic energy, as a 
prelude to pore creation, as suggested by Vaughan et al (Timothy E. Vaughan, 1996). For 
the pores of radius rpore = 1 nm and membrane edge energy density  = 2 × 10-11 J m-
1, the pore creation energy can be estimated to be 
 
Wpore  2  rpore  30 kT (39) 
 
Consequently, to generate pores of radius rpore =  10  and  20  nm,  the  energy  values  
needed are 300 and 600 kT, respectively. It can furthermore be assumed that the 
complexes used in the transfection treatment, having a diameter of 1.1 µm and 
containing a great number of nanoparticles, are stable structures generating as 
whole complexes rotational elastic energies.  
It follows from this that the rotational elastic energy provided by the pulses and 
magnetic transfection complexes is calculated to 
 
Wrot, elas ² · B²/2  784 kT (40) 
 
where  = 9.3 × 10-15 A·m² is the evaluated magnetic moment of the complexes, B = 
190 mT is the magnitude of the pulse and  = 0.968×10-18 Nm is the torsional spring 
constant of the cell membrane. 
This deployed energy is sufficient to invoke a cell membrane disruption and create 
pores that would allow the internalization of fragments of the complexes, specifically 
single or gathered particles with a size of about 20 nm or parts of the borne 
substances associated with the NPs and present in the complexes. Thus, the 
magnitude of the magnetic field pulse (at low frequency and with a magnetic flux 
density of 190 mT at the cell layer) and the magnetic moments of the magnetic gene 
delivery vectors applied in the transfection experiments satisfy the energetic 
constraints for creating cell membrane openings. These openings may be responsible 
for the increased transport of material into and out of the cell and for the observed 
increase in transfection efficiency compared with classical magnetofection using 
static magnetic fields (Ch. Dahmani, 2012). 
 
The results presented in this chapter, featuring increases in reporter luciferase gene 





endorse the model of cell actuation mechanisms. For instance, magnetic actuation or 
“nano-magnetic actuation” with alternating magnetic fields clearly enables the 
modulation of cellular uptake and trafficking of the magnetic delivery vectors. 
 
The enhancement of transfection efficiency through magnetic pulses comes as 
the ideal complement to the Magnetic Drug Targeting approach. The application of 
magnetic nanoparticles to the organism, followed by their guidance to and retention 
at target site, complemented by enhanced uptake and successful internalization of 
the carried bioactive load into the concerned tissue constitute the optimized 






6 Discussion and conclusions 
Gradually, targeted delivery of therapeutic substances by means of 
magnetically guided nanoparticles is proving to be a viable and promising new 
technology that still is in its ramp up phase. This thesis contributes to the advances 
achieved on this field through the exploration of a number of aspects of Magnetic 
Drug Targeting and through the development and validation of new solutions to 
implement it in-vitro and in-vivo. 
 
In this work, evidence has been provided, that appropriately generated 
magnetic fields can efficiently retain magnetic nanoparticles in the blood vessels. 
Results obtained in experiments on the dorsal skin-fold chamber model 
demonstrated the ability to concentrate therapeutic agents at a target site in the 
vasculature of an organism. The retention was reported in veins, but more 
importantly in arteries. The site directed delivery of therapeutic agents, including 
genes for gene therapy, is therefore a feasible technique and can be considered as a 
necessary complement of a systemic drug application, the expected main 
advantages being a significant reduction of side-effects at non-target areas and the 
better control of injected doses.  
However, the reported achievements were essentially based on the unprecedented 
proximity that has been reached between the blood vessels in the skin and the 
magnetic field source. A similar condition is yet relatively hard to fulfill under normal 
circumstances. When projecting the MDT as a future validated clinical application, 
the involved magnetic systems have to be advanced to a level that allows for strong 
field gradients at larger distances from the magnet tip. Tumors located deep within 
the body and not allowing the introduction of the magnetic system to their close 
surrounding would represent a dead zone for MDT application. Therefore, it is of 
utmost importance to further concentrate on the development of more 
sophisticated and stronger magnetic systems. A potential solution to overcome this 
problem can be for example the integration of field distortion and enhancement 
devices into a strong magnetic field generated by a magnetic resonance scanner, to 
produce high field gradients even at deeper organs in the body. These elements 
might also be intracorporal implants. Beyond this aspect, special care has to be taken 
regarding the emboli produced during nanoparticle retention. Especially in the case 
of capillaries, a blocking of the new blood supply could be the direct consequence, 
leading to damages of the organs or tissues irrigated by these vessels. On the other 
hand, selectively and reversibly embolizing parts of an organ’s vasculature can 





example of such an approach. 
In the part aiming at exploring Lung Drug Targeting, simulations have shown 
that a significant concentration and targeting of aerosols bearing magnetic 
nanoparticles in the lungs could be realized, provided intubation and magnetic field 
triggering are taken into consideration and adequately parameterized. Learnings 
generated through the in-vivo exams on the big animal model were integrated in the 
definition of the simulation setup and the CFD computations. For instance, 
intubation has been modeled and the airflow in the upper respiratory pathways has 
been simulated accordingly. It has been demonstrated that the assumption of a 
continuous laminar airflow has to be corrected through the consideration of a 
number of eddies especially in the transitional region between the main windpipe 
(trachea) and the bronchi. This is due to the high velocity of the inhaled air coming 
out of the intubation inlet. The same high velocity effect also causes a significant 
deposition of aerosols at the main bifurcation region (carina ridge). The intubation is 
on the one hand useful, as it enables avoiding unwanted aerosol loss in the mouth 
and larynx level, on the other hand, it has to be appropriately adjusted, for example 
through prolonging the used tubes to overcome the main bifurcation and eventually 
reach deeper compartments of the lungs. Here, it should be pointed out, that a 
requisite for deep intubation is the general anesthesia of the patient, which might 
encounter “acceptance” issues in clinical routine. 
The other major finding presented in this work is the impact of magnetic fields 
on  magnetically  active  aerosols  during  Lung  Drug  Targeting.  As  a  matter  of  fact,  it  
has been demonstrated that a significant agglomeration of nanomagnetosols in a 
region of the lungs exposed to a high magnetic field gradient can be reproducibly 
achieved. An optimal constellation of the studied parameters has been identified, 
mainly characterized by a relatively low air flow rate of 15 l/min, and the reported 
influence of time variant magnetic field activation has proven that it is indispensable 
to synchronize the magnet field with the breathing process for a selective trapping of 
magnetic aerosols. The embedding of real magnetic field data into the 
computational fluid dynamics simulation within a realistic geometry of the lungs has 
therefore led to a better understanding of the Lung Drug Targeting approach and the 
optimal intubation conditions. The limitation of these results remains though 
dependent on the simplified model and the assumptions related to the simulation. A 
consideration of all respiratory pathways is not feasible with the anatomical 
information available at the moment and given the computational capacity at hand. 
Despite the numerous hurdles encountered during implementation, simulating the 
LDT process can be a considerable contribution to the fine tuning of animal 
experimentations, mainly leading to the reduction of the number of those. 
 
The further significant achievement presented in this thesis relies in the 





guided nanoparticles. For instance, a magnetic system capable of generating defined 
magnetic pulses was constructed and used to investigate the effect of pulsating 
magnetic fields on the transfection process. The approach demonstrated increases in 
the transfection efficiency of up to 52% in adherent H441 cells and 70-90% in the 
reporter gene expression in Jurkat cells, compared with the use of a static magnetic 
field (standard magnetofection technique). Accordingly, magnetic fields can be used 
in every step of the nanoparticle based site-directed drug delivery technique, from 
guiding the nanocarriers within the organism, through their retention and 
agglomeration, to their internalization into the target cells and the deployment of a 
therapeutic effect. One of the key challenges facing these results is the transition to 
pre-clinical and clinical consideration. The pattern of exposure to the magnetic 
pulses has to be reproducible in the context of a human application of MDT. This 
means that novel magnetic systems, modified and adapted to suit an upcoming 
clinical use, have to be developed to generate the identified pulses. 
 
With  respect  to  the  monitoring  and  evaluation  of  the  success  of  an  MDT  
application, current approaches have to be revised and complemented. First, there is 
still no available solution to monitor -in real time- the nanoparticles’ advancement or 
distribution in the body during treatment, even if they are tagged with a specific 
moiety, such as fluorescent or radioactive substances. Given the concentrations 
involved in MDT, it is expected to encounter major difficulties, when trying to 
visualize the magnetic nanoparticles under X-rays or magnetic resonance imaging 
(MRI). Moreover, a post-mortem evaluation of the iron-content in the targeted 
organs or tissues is not applicable to a clinical use case. Therefore, special 
approaches have to be developed to tackle the visualization issue in the magnetic 






One of the most pertinent fields, where Magnetic Drug Targeting can have a 
significant contribution to the improvement of medicine, is undoubtedly cancer 
treatment. 
7 million deaths per year in the world can be attributed to cancer, representing 
approximately  12.5%  of  total  deaths.  It  is  believed  that  any  person  who  lives  long  
enough will eventually get cancer. 
However, strong signals emitted by the achievements realized in the last decades in 
cancer therapy suggest that medicine is capable of also surmounting this challenge. 
In fact, many of today’s established treatments were still in their experimental phase 
only a decade ago, so current clinical studies of new cancer therapy methods may 
translate into tomorrow’s treatment for most of the known tumor types. 
In analogy to traditional vaccines that have successfully prevented infectious 
diseases that were thought to be invincible, scientists continue to investigate ways 
to better understand, diagnose, and treat tumors. 
More recently, the great progress made in surgery, chemotherapy and 
radiation therapy, has led to the reduction of mortality caused by cancer. Gradually, 
traditional treatments are being supplemented with newer methods including 
chemoprevention and cancer vaccines. A further, particularly promising approach, 
are Nanotechnology-based efficient drug delivery systems. Here, the intrinsic, size-
based proximity between nanostructures and the elementary constituents of the 
organism (cells and cell organelles) suggests a better interaction and an enhanced 
therapeutic effect. The use of engineered nano-devices and nanostructures, at the 
single cell level, is expected to ultimately change the way medical benefit is 
achieved. 
In accordance with these outlooks, Magnetic Drug Targeting essentially 
enhances the specificity and selectiveness of chemotherapy. It offers a new way to 
carry drugs specifically to tumors, which would help resurrect promising drugs that 
failed in clinical trials because they were cleared from the bloodstream before they 
could reach their intended targets, or had to be given in doses high enough to 
produce toxic side effects. 
Furthermore, MDT enables new treatment approaches, such as gene therapy. 
In future projections of medical treatments, the underlying principle of healing is 
expected to evolve from the conventional destroying or eliminating of a malignant 
tissue  to  its  preservation,  repair  and  improvement.  Here  too,  MDT  presents  an  
enormous potential. For instance, it can be applied to advance immunotherapies 





cancer cells. Mobilization of the human body itself against cancer may, in fact, 
provide a very attractive alternative or complement to conventional chemotherapies 
and radiation therapy. 
This is but one of the many examples where nanotechnology will bring about 
the development of the so-called regenerative medicine, towards a cell-by-cell 


































„Der Geist der Medizin ist leicht zu fassen! Ihr durchstudiert die groß - und kleine 
Welt, um es am Ende gehn zu lassen, wie's Gott gefällt.“ (Mephistopheles) 
 
Johann Wolfgang von Goethe 
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